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Abstract
Quantum dots (QDs) are semiconductor nanoparticles which have emerged as powerful 
fluorescent probes for biological imaging applications due to their unique size-dependent 
optical and electrical properties. QDs have several advantages over small organic dyes and 
fluorescent proteins such as size-tunable photoluminescence, wide excitation-narrow 
emission properties, improved brightness and high resistance to photobleaching and 
degradation. So far QDs have been used to track individual biomolecules, but for this 
application a widespread concern is that biomolecules can lose activity when they are 
attached to QDs because these are multivalent and large. Thus, recent attention has turned 
toward labelling strategies which enable site-specific recognition and controlling the number 
of molecules that can be attached to a single QD down to a single molecule with retention of 
activity. Apart from showing ability to recognise appropriate biological partners, relatively 
little is known about the biological activity o f biomolecules attached to QDs.
In this thesis various strategies for preserving and enhancing the activity of 
biomolecules on QDs were developed to address and investigate these aspects and to extend 
the biological applications o f QDs.
Nitrilotriacetic acid (NTA)-modified QDs were used for site specific labelling o f a 
hexahistidine (His6)-tagged Glutathione-S-Transferase (GST). GSTs catalyse nucleophilic 
substitution reactions between glutathione and a wide range o f endogenous and xenobiotic 
electrophiles, which makes them important detoxifying enzymes and anticancer targets. The 
hydrophobic CdSe-ZnS (core-shell) QDs were made water soluble by ligand exchange with 
dihydrolipoic acid and coupled to NTA-Ni via an amide bond. Ni-NTA capped QD were 
capable o f binding recombinant S. japonicum  His6-GST selectively. As a result o f the His6 
tag’s ability to provide a docking site for the QD away from the active site, the GST 
molecules bound to these QDs retained their catalytic activity. In contrast, the non specific 
binding which takes place in the absence o f the His6 tag leads to loss o f catalytic activity.
Hydrophobic interactions were used to functionalize CdSe-ZnS QDs with Kdo2-lipid A 
-the lipopolysaccahride (LPS) present in the outer membrane o f E.coli. These constructs 
were used as pathogen models to investigate how pathogens and pathogen associated 
molecular patterns (e.g. LPS) interact and are processed by the immune system. The ability of
QDs to enhance the biological activity o f a biomolecule was demonstrated in vitro and in vivo 
for the first time. QD-LPS micelles were able to induce stronger production o f cytokines in 
macrophages and dendritic cells in vitro and a model antigen (DNP-OVA) in vivo than 
control LPS.
Also presented in this thesis is the first attempt to exploit the multivalency and site 
specific labelling properties o f NTA-Ni-decorated QDs to mimic the surface o f a parasite. 
The focus here was on the Plasmodium falciparum  malaria merozoite, which has MSP 1 as 
major component o f its surface. Conjugation o f a recombinant form o f His6-MSP-l hybrid to 
three different types o f NTA-Ni-decorated QDs was accomplished. Morever, by changing the 
linker units separating the QDs and Ni-NTA complexes it was possible to control the number 
o f MSP 1 molecules attached to each QD.
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Chapter 1
1.1 Nanotechnology
Nanotechnology (from the Latin nanus and Greek nanos for dwarf) is the science which deals 
with materials having dimensions between 0.1-100 nm (1 nm = 10 m) (Figure 1.1). These 
materials are called nanomaterials. Nanotechnology is a fast growing field which uses the 
knowledge of various fields like materials science, interface and colloid science, 
supramolecular chemistry, chemical engineering and biological engineering.1 In 1965 Nobel 
laureate Richard Feynman said “There is plenty o f room at the bottom”. His vision has been 
proven correct by the unprecedented growth o f nanotechnology during last decade or so.2 
An important feature of nanomaterials is that they exhibit properties which are different from 
those of small molecules and bulk materials, as will be illustrated below with representative 
examples.3
Atom Small Dye Fluorescent Colloidal Bacterium Animal 
Molecules Proteins Gold Cell
F IT C
G F P  P E
I < i it  m il i i  i  m ill  i i 11  m il i i m i n i  i i m in i  i i i n  ml
1À 1 nm 10 nm 100 nm 1 pm 10 pm 100 pm
Q d o t
N ano crystal
Figure 1.1 Nanometre-Sized Comparison (taken from Rosenthal et a!.3).
1.2 Colloidal Nanoparticles
1.2.1 Colloids
The term colloid is originated from the greek word ‘kolla’ for glu. Colloids are biphasic 
mixtures which contain a dispersed phase (or discontinuous phase) dispensed uniformly in a 
finely divided state in a dispersion medium (or continuous phase). In colloidal systems the 
dispersed phase lies in the 1-100 nm range, and therefore they are an important class o f 
nanomaterials. Colloidal systems, like other nanomaterials, have high surface-to-volume
1
Chapter 1
ratios and this is important for many applications. When a beam of light is allowed to pass 
through a colloidal dispersion, the path o f light gets illuminated. This phenomenon was 
observed by John Tyndall in 19th century and so called the “Tyndall effect” . Colloids and 
colloidal nanoparticles have been important for many centuries. Alchemists used two 
important forms o f colloidal gold, namely potable gold and Purple o f Cassius, for making 
ruby glass. In 1856 Michael Faraday prepared and studied the first colloidal gold by reducing 
an aqueous solution of gold chloride with phosphorus to form a ruby coloured liquid. Some 
common examples o f colloids are milk, fogs, smoke, hair sprays, pigmented ink and blood 






Liquid Gas Liquid aerosol F o g , sprays
Solid Gas Solid aerosol Smoke, dust
Gas Liquid Foam Foams
Liquid Liquid Emulsion M ilk , mayonnaise
Solid Liquid ‘Sol’ or colloidal solution 
Paste at high concentration
Au sol, Ag sol 
Toothpaste
Gas Solid Solid foam Expanded polystyrene
Liquid Solid Solid emulsion O p a l, pearl
Solid Solid Solid suspension Pigmented plastics
Table 1.1 Classification of colloidal systems
1.2.2 Classification and applications of colloidal nanoparticles
Colloidal nanoparticles can be classified on the basis o f the type o f material they are made of 
into organic and inorganic nanoparticles. Various other criteria are used to characterize these 
systems including particle size, polydispersity, colloidal stability and surface charge density.5 
Nanoparticles are also widely used in biology and medicine due to their unique size 
dependent properties. A nanoparticle having various functional groups can be used for 
targeting specific receptors and cells. Paul Erlich proposed this concept at the beginning of 
the 20th century and it was called ‘magic bullet’.6 Inorganic nanoparticles made o f gold, 
silver, iron and platinum are used for a variety o f purposes including biomolecular 
recognition,7 delivery,8 sensing,9 tissue engineering,10 MRI contrast imaging.11 Noble metal 
(e.g. gold and silver) nanoparticles demonstrate surface plasmon resonance (SPR). In SPR the 
surface of these metals is exposed to electromagnetic radiation. The free electrons in the 
metal (d electrons in silver and gold) are polarized to one surface by the incident light and 
oscillate in resonance with the radiation frequency forming a standing oscillation (Figure
2
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1.2). For instance, this oscillation results into a characteristic absorption peak at 520 nm for 
gold nanoparticles. Molecules which are bonded to the metal can cause a change in the 
electron density on the nanoparticle surface leading to shifts in the SPR absorption 
maximum.12
Nanopaiticlc Inverse of Elections
Incoming Light on Nanopaiticlc
Surface
Figure 1.2 Origin of surface plasmon resonance due to coherent interaction of the electrons in 
the conduction band with light (taken from Eustis et al.12).
Thus, gold and silver nanoparticles are widely used for detecting biomolecules in DNA 
analysis,13 immunoassays14 and bioimaging applications15 (Table 1.2). Non-noble metal 
nanoparticles like iron nanoparticles are widely used in protein purification, separation and 
concentration. Their magnetic properties make their isolation very easy after binding to 
proteins.16
In some cases more than one type of metal nanoparticle is used in the same experiment 
because they bring complementary features. For example, in a recent study magnetic 
microparticles (MMPs) were coated with a primary antibody targeting a specific antigen like 
prostate specific antigen (PSA). Gold nanoparticles were immobilized with a secondary 
antibody for PSA, and through a sense strand to multiple short DNA duplexes that are unique 
to PSA. After MMPs with the primary antibody react with antigen and subsequently with the 
gold nanoparticles having secondary antibody, they can be easily separated from unbound 
species taking advantage o f the magnetic properties o f the MMPs. The antisense strand can 
be released from the MMP-nanoparticle assembly by heating and the amount of 
oligonucleotide can be determined by using a DNA microarray (Figure 1.3). Because the 
mixed nanoparticle assembly carries many copies o f DNA per protein binding event, the 
signal is significantly amplified and PSA could be detected at 30 aM (10"18 M) concentration 










13 nm NPs for Bio-Bar-Code PCR 
30 nm NPs for PCR-less Method
Step 2.
Sandwich Captured Target 
Proteins with NP Probes ^
Step 5.
Chip-Based Detection 




of Bar-Code DNA 
30 nm NP Probes
Step 3.
MMP Probe Separation 
and Bar-Code DNA 
Dehybridization______
Figure 1.3 The bio-barcode assay method (taken from Nam et a!.17).
Name of particle Size Domain Example of 
applications
Inorganic nanoparticles
1 .Gold nanoparticles 10-30 nm Colorimetric detection of 
DNA sequences
2. Silver nanoparticles 2-10 nm Protein purification
3. Iron nanoparticles 2-10 nm Medical imaging
4. Platinum nanoparticles 2-10 nm Labels for chip-based 
DNA detection
5.QDs 2-10 nm Detection and 
quantification o f biological 
molecules
Organic nanoparticles
1. Carbon nanotubes and 
fullerenes
A few nanometers DNA targeting
2. Dendrimers 10-50 nm DNA chips
3. Polyelectrolyte 
(complexes natural and 
synthetic polymers)
50-200 nm Drug targeting, 
Vaccination
4. Self-assemblies of 
polyethylene oxide block 
copolymers
50-200 Stealth drug delivery 
systems
5. Latexes 20-1000 nm Solid-phase assays, 
vaccination, two 
dimensional arrays
Table 1.2 Various colloidal nanoparticles with applications.
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1.2.3 Synthesis of colloidal nanoparticles
Colloidal systems are commonly synthesized by precipitation,5’18 polymerization5,19 and self 
assembly processes.5’20 Inorganic particles like those made of gold or silver are typically 
prepared by a precipitation process (Figure 1.4) involving three steps. In the first step metal 
ions are reduced to metal atoms. In the second step these metal atoms aggregate forming a 
small nuclei having diameter o f less than 1 nm. In last step further growth o f the nanoparticle 
takes place by the deposition o f atoms or microclusters on the newly formed nuclei. Usually a 
water-soluble polymer (e.g. poly(N-vinyl-2-pyrrolidine, PVP) is added to stabilise the final 
metal nanoparticles (Figure 1.4).5 Semiconductor nanoparticles, which are the focus o f this 
thesis work, can also be prepared adopting the precipitation method (see below). In contrast, 
organic nanoparticles are most commonly made by the polymerization method. For example 
by polymerization o f an organic monomer dispersed in aqueous phase in the presence o f an 
emulsifying agent after the addition o f a radical initiator (Figure 1.5).19





Figure 1.4 Formation of a metal nanoparticle by reduction with an alcohol of metals salts in the 
presence of of poly(A/-vinyl-2-pyrrolidone)(PVP) as stabilizer.
V r
j ^  Monomer/
( Solvent A Emulsifier I £» C  Solvent B
I Continuous ultrasonffication | j ^ — high speed
! Phase I stirring
t§ “  r
¡ft 4
r *  *
Polymerization
Cl C* m.
( r r  C  Isolation 
• of t he • * * *
C ®  , product
€  C •  C
Figure 1.5 Polymerization of olefins in a perfluoralkane/alkane mixture (taken from Larpent et
al.19).
Preparation of colloidal nanoparticles via self-assembly is mostly done by processes which 
involve micelles. Micelles are formed when the surfactant concentration exceeds the critical
5
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micelle concentration (CMC) in water. In normal micelles, the hydrophobic hydrocarbon 
chains of surfactants are directed towards the interior o f the micelle and the hydrophilic 
groups are pointing outwards to interact with the aqueous medium surrounding the micelle 
(Figure 1.6). This method can be applied to prepare stable and biocompatible semiconductor 
nanoparticles (see below). In reverse micelles, hydrophilic groups are oriented towards the 
core of micelle and hydrophobic groups are terminated outwards (Figure 1 .6).20
A B
H ydrophilic head H ydrophobic tail
Figure 1.6 Architecture of (A) normal and (B) reverse micelles.
1.3 Quantum Dots (QDs)
QDs are nanocrystals o f semiconductor materials with a size range o f 1-10 nm, and therefore 
they contain from several hundreds to a few thousand atoms. QDs are sometimes referred to 
as ‘artificial atoms’ because like an atom or a discrete molecule (and unlike bulk 
semiconductors) they have discrete energy levels (Figure 1.8).21
The most widely used QDs are made of group II-VI elements i.e., cadmium sulphide (CdS),22 
cadmium selenide (CdSe), 22 cadmium telluride (CdTe), 22 zinc selenide (ZnSe), 23 and 
mercury telluride (HgTe).24 Sometimes these semiconductor cores are also coated with 
another semiconductor material (e.g. ZnS shells for CdSe cores) for protecting against 
oxidation and degradation, improving emission properties etc. o f the QD.25 These are referred 
to as core/shell QDs. In this thesis, the work is focussed on CdSe/ZnS (core/shell) QDs. The 
surface of QDs is also coated with organic ligands which further tune the physical and 
chemical properties o f the QD (Figure 1.7).26
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Figure 1.7 Quantum dots composition core and core/shell (X represents the groups attached to 
QD surface, L represents the linker and Y represents groups forfunctionalization).
1.3.1 Optical properties of QDs
There are significant differences between the electronic and optical properties o f QDs and 
bulk semiconductors which make these materials o f considerable current interest. In a bulk 
semiconductor the energy levels in the valence and conduction bands are continuous whereas 
in QDs energy levels are discrete (Figure 1.8). When an electron jumps from the valence 
band to the conduction band it forms a hole in the valance band and the hole-electron pair is 
called an exciton. The distance between hole and electron is called the exciton Bohr radius27 
and varies from material to material.28 When the radius o f the semiconductor crystal becomes 
smaller than the exciton Bohr radius then the density o f states becomes more like that found 
in discrete atoms.29 This causes the band gap energy to increase and depend upon the size o f 
the nano crystal.
Bulk Quantum dots 
semiconductor (QDs)
Figure 1.8 Energy level diagram for semiconductors and QDs.
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Thus, for exciting an electron in a QD, the energy required is always higher than the band gap 
energy for the bulk material (Eg) (Figure 1.8). As a result the absorption spectrum o f QDs 
reflects atomic-like transitions o f which the so-called ‘first absoption peak’ or first ‘excitonic 
peak’ is the lowest energy required to excite an electron.30,31 A typical absorption spectrum 
for a CdSe QD is shown in Figure 1.5.
Wavelength (nm)
Figure 1.9 Absorption spectrum of a CdSe QD.
The position of this peak for QDs of the same semiconductor material will be different for 
different sizes. This is because the electrons behave like ‘particles in a 3D box’.
For a particle in a ID box the particle energy is proportional to the dimension o f the box 
(1/d2) as follows
Eweii,id = 1/8 h'/md" (where h = Plank’s constant, m = free electron mass and d = width of
well)
For a QD the box is a sphere and thejowest energy level is then
Ewell,3d(sphere) 1/2 h /md~




The first contribution is the band gap energy for the bulk material Eg(buik)- Another important 
contribution comes from the confinement energy which is
E w e l l  = E w e i i ( E ' )  + Eweii(h+) = h2/2m*d2 (1) (E‘ represents the electron, h+ represents the hole; 
m* is the reduced mass o f exciton ). hi this expression m* is given by
1/m* = l/m e+ l/m h (where me= effective mass o f electron and mh= effective mass o f hole)
For a large particle (bulk: d -> oo) so this energy tends to become zero.
For calculating the energy required to create an electron-hole pair a Coulombic interaction 
tenns (Ecoui) has to be considered. This Coulomb interaction is based on the attraction 
between the electron and the hole multiplied by a screening coefficient which depends on the 
dielectric constant of the semiconductor s and dielectric constant o f vacuum s0. Because d is 
small for a QD then this term can also be significant.
Ecoui = -1.8 e2/27rss0d (2)
Thus, estimating the size-dependent energy gap of a spherical shape QD can be done by using 
following equation.
Eg(dot) = Eg (bulk) + Eweii + Ecoui (3)
So by inserting equation (1) and (2) into expression (3) we get 
Eg(dot) = Eg (bulk) + h2/2m*d2 -1 .8  e2/27tss0d
So the band gap for QDs depends upon two size dependent terms: the confinement energy 
which changes as a function o f 1/d" and the Coulomb attraction which changes as a function 
of 1/d. Thus, quantum confinement becomes very important in small QDs.32
When the hole and electron recombine, it results into emission o f light by fluorescence,33 
which therefore is also size-dependent. As the size o f the QD decreases the band gap 




o o o Q  Q
1 nm -—    ► 20 nm
Size
Figure 1.10 Emission spectra of different size CdSe nanoparticles (taken from Zhou et
al.34).
1.3.2 Synthesis of QDs
Because QDs are nano crystalline materials, their formation involves a nucléation and crystal 
growth process. In 1950 LaMer and Dinegar proposed that the formation o f colloids of 
sulphur occurs by a nucléation process which depends on the concentration o f precursor, and 
that is followed by incorporation o f the remaining precursors in solution to these initially 
formed nuclei.35 In this model, when the solution is supersaturated and reaches a critical 
threshold then nucléation starts, causing a drop in the concentration. The nucléation process 
stops once this drop in concentration reaches a critical threshold value, at which point the 
nuclei formed grow.35 QD synthesis employs the same principle but at higher temperatures. 
Synthesis of QDs is commonly done by the hot-injection method. As the name suggests in 
this method nucléation and growth of particles is achieved by rapid injection o f reagent into 
hot solvent, which quickly increases the precursor concentration in the reaction mixture 
above the nucléation threshold. This starts the nucléation process which can be quenched by 
fast cooling after achieving the desired QD size (Figure 1.11).36
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Figure 1.11 Stages of nucleation and growth for the preparation of QDs (taken from Murray et
a i r b).
1.3.2.1 CdSe core (nanoparticle) synthesis
One of the first colloidal QDs were produced by Ramsden and Graztzel37 by adding H2 S to an 
aqueous solution of Cd(N0 3 ) 2  or by rapid mixing of Na2 S and Cd(N0 3 )2 - They reported 
luminescence data and transmission electron microscopy (TEM) images o f the particles 
formed. In 1985 Nozik et al,38 found that size quantization has a very significant effect on the
optical properties o f CdS and PbS colloidal properties.Two years later Henglein developed
• . • . 9+ • *1further the synthesis and properties o f CdS nanoparticles by first precipitating Cd ions with
stoichiometric amounts of H2 S (injected in) followed by the addition o f NaOH and excess
2"h • JCd“ ions. In this synthesis the creation of a shell o f the large band gap material Cd(OH ) 2  on 
the surface o f CdS nanoparticle act as fluorescence activator. This provides an electronic 
barrier at the surface of the nanoparticles, which prevents the charge carrier from escaping
'2Q
the core. In 1988 Streigerwald and Brus demonstrated that IR, NMR and X-ray 
photoelectron spectroscopies, in conjunction with scanning and high resolution electron 
microscopy can be used to characterise QDs,40 which was an extraordinary advance in terms 
of particle characterization.
Murray et al.4 I reported the first synthesis o f CdSe nanoparticles using organometallic 
compounds,42̂ 4 and found that these are excellent precursors in QD synthesis. The method is 
based on the pyrolysis of organometallic reagents like dimethyl cadmium and 
bis(trimethylsilyl) selenium by injection into hot coordinating solvents like tri-n- 
octylphosphine oxide (TOPO) and tri-n-octylphosphine (TOP). In this method, the 
coordinating solvent provides temporary discrete nucleation and permits controlled growth of 
nanocrystals. The reaction involves combining the appropriate metallic or organometallic
11
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precursors (zinc, cadmium or mercury species) with the corresponding chalcogen precursors 
(sulphur, selenium or tellurium species) in a coordinating solvent at high temperature. 
Preferably TOPO is used due to its surfactant properties. Sometimes TOPO is used in 
combination with other surfactants or co-solvents such as TOP, TBP, hexadecylamine or 
stearic acid. In these reaction conditions, particle nucleation takes place in a very short time 
span, and is followed by epitaxial growth and nanocrystal annealing at slightly lower 
temperature.45 Epitaxial growth reaches a point where the size distribution is narrow. The 
larger particles grow from the smaller more soluble particles (Figure 1.11).46 This point is 
also called the bright point because from this point photoluminescence efficiency decreases.47 
At this point the reaction is quenched by lowering the temperature. This is the most reliable 
and reproducible procedure for the synthesis of high-quality QDs.48 Nanoparticle size and 
growth can be manipulated to a certain extent by controlling the initial precursor 
concentration, temperature and length o f growth period. This method yields samples with 
narrow distributions (<5% rms in diameter) having uniform size, shape and surface 
passivation. This method has been applied to QDs with CdS, CdSe and CdTe cores, leading 
to nanocrystals with sharp absorption and emission features at room temperature, and ~ 10- 
times brighter fluorescence than Rhodamine 640.41,48
Peng et a l49 have developed a new approach for the synthesis o f CdS and CdSe nanoparticles 
which involves the reaction o f CdO as cadmium precursor and hexylphosphonic acid or 
tetradecylphosphonic acid as ligands. This was the first study in which non-pyrophoric 
precursors are used, making QD synthesis safer and less expensive. This new synthetic 
procedure works significantly better than the previous synthesis based on the use o f dimethyl 
cadmium as a cadmium source. Moroever, this approach for synthesizing high-quality 
semiconductor nanocrystals works under mild conditions and is simple, making it well suited 
for bulk nanoparticle synthesis.
All these methods are based on the hot-injection technique. However, an alternative QD 
synthetic procedure involves mixing precursors at room temperature and subsequent heating 
to a certain temperature to initiate nucleation; this method is called the heating-up method. In 
2005 Cao s group synthesised CdSe QDs without using phosphine ligands using the 
heating-up method. Phosphine ligands are air, moisture-sensitive and costly compounds. 
They used cadmium myristate as a cadmium precursor because myristate decomposes above 
226 C. Elemental selenium was used with octadecene (a non-coordinating solven) for the 
CdSe core synthesis because octadecene dissolves selenium above 190 °C. Thus, the
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formation of CdSe is possible at a temperature o f ~ 240 °C. Nowadays octadecene is widely 
used in QD synthesis because o f its physical properties (liquid at room temperature), lower 
price and environmentally friendly nature.
1.3.2.2 Shell Growth
It was found that defects on QD particle surfaces and poor surface passivation can reduce the 
fluorescence quantum yields. For improving the quantum yield o f these materials the 
semiconductor core can be capped with a wider band gap inorganic layer. The main 
advantage o f capping the core is that the exciton photogenerated in the core is protected from 
the environment, preventing non-radiative recombination pathways. These QDs are often 
referred to as core/shell QDs.25
Bawendi et a l25 and Hines et al.51 synthesized the first prototype o f core/shell QD. ZnS- 
capped CdSe QDs were prepared by using organometallic reagents in a two-step single-flask 
method (Figure 1.12). In this method, purified CdSe nanoparticles are suspended in 
coordination solvent. The capping material, usually diethyl zinc and hexamethyl disilathiane 
dissolved in TOP are then slowly added at elevated temperature (Figure 1.8). The 
temperature chosen for this addition is very important. It should be high enough to favour 
epitaxial crystalline growth but low enough to prevent nucléation o f ZnS crystal and Ostwald 
ripening of CdSe core. Thus, the shell growth temperature is around 160-220°C. ZnS capping 
increases the particle size o f QDs, resulting in a red shift o f the photoluminescence 
wavelength. At the same time Danek et al.52 provided another example o f a core/shell QD by 
passivating CdSe nanocrystals electronically and chemically with a ZnSe. Some typical 
examples of core/shell QDs include CdS shell on CdSe core,25 ZnS shell on CdSe core,25 ZnS 
shell on CdS core,53 and CdS shell on CdSe core.54
Figure 1.12 Scheme for making CdSe/ZnS QDs (taken form Bailey et a!.55).
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Recently Zhu et a l56 developed a phosphine-free synthesis o f CdSe/ZnS (core /shell) QDs. 
They reported a simple method for making QDs by using cadmium stearate, oleylamine, 
paraffin liquid, zinc acetate dihydrate and sulphur powder. The shell o f ZnS was grown over 
the CdSe core by using the seeding growth technique. In this technique first the shell was 
made by mixing Zn and S precursors in the CdSe core reaction mixture. This growth cycle 
was repeated many times for yielding desirable size core/shell QDs.
1.3.3 Water Solubilization of QDs
QDs are generally synthesised using organic solvents thus they are hydrophobic in nature. 
This makes them unsuitable for biological applications. It is therefore important to make 
them hydrophilic. There are three main approaches to prepare water-soluble QDs: 1) 
hydrophobic ligands on QDs surface are replaced by bifunctional hydrophilic ligands, 2) 
hydrophobic QDs can be encapsulated in amphiphilic polymers by using hydrophobic- 
hydrophobic interactions to provide water-soluble QDs and 3) hydrophobic QDs can be 
encapsulated in a silica shell which imparts protection from the environment and water 
solubility.
1.3.3.1 Ligand Exchange
QDs synthesised in organic solvents have TOP, TOPO,41,57 tetradecylphosphonic acids57 or 
oleic acid50 on the surface. These hydrophobic ligands can be replaced by water-soluble 
bifunctional ligands (Figure 1.13). In these ligands one end binds to the QD surface, and the 
other, has functional groups free for reaction with biomolecules and to confer water 
solubility.57 Typical biofunctional ligands are mercaptocarbonic acids,58 2- 




Figure 1.13 Water solubilization strategies for hydrophobic QDs by ligand exchange using 
dihydrolipoic acid (taken from Zhou eta l. ). » a
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1.3.3.2 Encapsulation by amphiphilic polymers
Phospholipids like 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy 
(polyethylene glycol)] and l,2-dipalmitoyl-sn-glycero-3-phosphocholine have both 
hydrophobic and hydrophilic moieties. The hydrophobic ends form a core inside which QDs 
can be encapsulated by forming oil-in-water micelles through hydrophobic interactions 
(Figure 1.14). These micelles provide aqueous solubility via the hydrophilic exterior ends o f 
the phospholipids.65,66,67 In another interesting approach polyacrylic acids were partially 
cross-linked with octylamine using 1-ethyl-3-[3-dimethylaminopropyljcarbodiimide (EDC). 
This makes them amphiphilic and capable o f forming micelle-like structures with carboxylic
/o
acid groups pointing outwards which encapsulate QDs in the core. Incorporation of 
polyethylene glycol (PEG) in the surface o f QDs is useful because o f its low toxicity and 
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QDs can also be encapsulated in silica for water solubilization.69,70 In a typical procedure
QDs are embedded in a siloxane shell and then functionalized with thiol and/or amine groups 
(Figure 1.15).69 Introduction of these organosilicone molecules on the QD surface, however,
simple, yet effective strategy in which CdSe QDs were embedded in silica by using the 
reverse micro emulsion technique having a quantum yield o f 20% in water (compared to 17% 
for typical hydrophobic CdSe/ZnS QDs). In general, S i0 2-coated QDs show less in-vitro 
cytotoxicity than other water soluble QDs (e.g. coated with mercaptoacetic acid).
Figure 1.15 Scheme showing silanization method and subsequent functionalization with F = 
amine, thiol, phosphate etc. (taken from Gerion et al.69).
1.3.4 Bioconjugation to QDs
For biological applications QDs are conjugated to various biomolecules. It is very important 
that the activity of conjugated biomolecules is retained so that they can be used further in 
various biological applications. There are two strategies for attaching biomolecules on QDs: 
using covalent and noncovalent linkages.
1.3.4.1 Covalent attachment
There are two common covalent linkage strategies for cross linking biomolecules on QDs. 
These strategies are carbodiimide-mediated amide formation (using EDC)58 and active ester 
maleimide-mediated amine and sulfhydryl coupling71 (using sulfosuccinimidyl 4-[N-




maleimidomethyl] cyclohexane-l-carboxylate (sulfo-SMCC)) (Figure 1.16 and 1.17). There 
is an advantage in using the carboxylate-amine condensation method in that most proteins 
contain primary amines and carboxylic groups which can be used for carbodiimide-mediated 
amide formation. The disadvantage is that it does not provide control over the site o f 
attachment. Free sulfhydryl groups are rarely found in proteins and they are usually unstable 
in presence o f oxygen. This makes this approach less widely applicable but it provides better 
site-specificity than amide bond formation.
Chan et al.5H used carbodiimide coupling chemistry to link transferrin and immunoglobulin G 
(IgG) to mercaptoacetic acid coated QDs (CdSe/ZnS), and these proteins were able to still 
bind to their appropriate biological partners.
cih/—N
Figure 1.16 Covalent coupling between carboxylic acid (-COOH) coated QDs and primary 




Figure 1.17 QD conjugation to antibody fragments via disulphide reduction and sulfhydryl- 
amine coupling. J 1
Pathak et a l60 prepared water-soluble QDs by coating them with dithiothreitol. These 
hydroxyl-terminated QDs were then coupled with different oligonucleotide sequences via a
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carbamate linkage. This linkage led to conjugates that were stable for months and have high 
aqueous solubility. Further these QDs-oligonucleotide conjugates were used in detection o f 
chromosome abnormalities or mutations by using fluorescence in situ hybridization (FISH) 
procedures.
Pellegrino and coworkers72 used QDs coated with a preactivated amphiphilic polymer 
containing multiple anhydride units which are highly reactive towards primary amines, 
allowing attachment o f proteins via the formation o f peptide bond linkages. This method can 
be very useful for making biodegradable drug delivery systems.40
Mitchell et a lP  used 3-mercaptopropionic acids to passivate the QD surface so that it can 
easily displaced by alkyl thiol-capped oligonucleotides. This was the first attempt where 
nanoaparticle were modified successfully with single stranded DNA.
1.3.4.2 Noncovalent attachment
Electrostatic interactions, biotin-streptavidin linkages and direct absorption o f biomolecules 
on QD are three types o f non-covalent linkage used for attaching biomolecules on QDs. 
Electrostatic interactions are based on electrostatic attraction between QD and biomolecules 
(Figure 1.18). For example, Mattoussi and co-workers74 conjugated lipoic acid-capped 
CdSe/ZnS QDs with a negatively charged surface to a recombinant protein having a maltose 
binding protein attached to a positively charged leucine zipper domain at the C-terminus. In 
another study, Dixit et al.ls encapsulated QDs inside a viral capsid. This process is driven 
primarily by electrostatic interactions between negatively charge QDs and the positively 
charged internal compartment of the brome mosaic virus (BMV) capsid. In this study QDs 
were coated with four different types of ligands: lipids, DNA, DHLA and HS-PEG-COOH. 
Niemeyer et a lP  used electrostatic interaction between positively charged cytochrome 
P450Bsb and negatively charged mecaptoacetic acid coated CdS and CdSe QD for 
bioconjugation.
o




Mattoussi and co-workers77 reported a new non-covalent coupling strategy for linking
biomolecules on QDs. CdSe/ZnS core/shell QDs were attached to polyhistidine tagged
2_)_
proteins (Figure 1.19) exploiting the high binding affinity o f histidine for the metal (Zn~ ) 
rich surface o f the QD (CdSe/ZnS). In this way, several his-tagged peptides and proteins,
78
including a maltose binding protein (MBP) were successfully attached to QDs.
Figure 1.19 Scheme showing QD conjugation to biomolecule using coordination bonds (taken 
from Sapsford et al.77).
Streptavidin is a protein that has very high affinity for biotin (Kd = 10'15 M) and therefore can 
be used for attaching QD-streptavidin conjugates to biotinylated biomolecules or vice-versa 
(Figure 1.20). In general, QDs are targeted to the protein o f interest using biotin-streptavidin 
recognition using a three-layer strategy involving a primary antibody which binds to the 
target protein, a QD coated with streptavidin and biotinylated secondary antibody which 
binds the primary antibody and the QD.79 Another approach used by Bruchez et a/.80 involved 
attaching covalently streptavidin to QDs and used these streptavidin-coated QDs to label F- 
actin filaments on fibroblasts by using biotinylated phalloidin, a molecule which specifically 
binds to filamentous F-actin but not to globular G-actins. This method was very effective and 
did not lead to non-specific binding to other parts o f cells. Howarth et a/.81 used a streptavidin 
conjugated QD to specific proteins by tagging them with a 15-amino acid acceptor peptide 
(AP) which is specifically biotinylated by the E. coli enzyme BirA. The advantage o f this 







Figure 1.20 Noncovalent conjugation of streptavidin-coated QDs to biotinylated antibodies 
(taken from Xing et al.82).
In a different approach CdSe/ZnS semiconductor nanocrystals were immobilized with 
synthetic phytochelatin related peptide (Figure 1.21).83 These synthetic phytochelatin-related 
peptides have hydrophilic linker domain made up o f glutamic acid residues and adhesive 
domain composed of multiple repeat units o f cysteines pairs. The adhesive domain is used for 
anchoring peptide on nanocrystals while aqueous solubility is provided by hydrophilic 
domain.
O  CdSe/ZnS nanocrystal V n - Peptides
Solubilization %  Purification
Peptide: G-S-E-S-G-G-S-E-S-Gj-Clm-CC-Cha-C-C-Cha-C-C-Clia 
Hydrophilic linker domain Adhesive domain
Figure 1.21 Schematic representation of the surface coating chemistry of CdSe/ZnS 
nanocrystals with phytochelatin-related a-peptides (taken from Pinaud et al.83).
1.4 Fluorescent tool box for biological labelling
Visualization, tracking and quantification o f molecules and events in living cells with high 
accuracy and precision provide a platform to understand these complex systems. There are 
three types of tools which are widely used in fluorescence cell labelling: small organic dyes, 
fluprescent proteins, and since recently, QDs.84 Small organic dyes have long history as a 
labelling agent in biology. Organic dyes commonly used in biology are fluoresceins, 
rhodamines, cyanine dyes and alexa dyes. There are some limitations with organic dyes like 
short Stokes shift, low photo stability and high susceptibility for photobleaching. But their low 
cost, availability and easy to use property makes them very popular in cell labelling.85 
Fluorescent proteins are also popular for bioimaging applications. The first fluorescent
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proteins used in cell labelling were phycobiliproteins and photosynthetic antenna pigments 
extracted from cyanobacteria. Phycobiliproteins contains multiple bilin chromophores 
encapsulated in a protein matrix for minimising self-quenching, making them two times 
brighter than organic dyes. But their large size (~ 200 kD) limits their usage in many 
labelling applications.84 They are more often used with antibody conjugates for surface 
labelling in flow cytometry and enzyme linked immunoassays. A new era in cell labelling
85-87was started after the discovery and development o f green fluorescent proteins (GFP). 
GFP was first isolated from jelly fish Aequoera victora86 and later it was cloned.87 In 2008 
the Noble prize for chemistry was awarded to Osamu Shimomura, Martin Chalfie and Roger 
Y. Tsien for the discovery and development o f the GFP which shows the importance o f these 
proteins in cell labelling. As the name suggests GFP emits green fluorescence under 
excitation by U.V. light. The chromophore which is responsible for absorbance and 
fluorescence of GFP is p-hydroxybenzylidene-imidazolidinone. Expression o f green 
fluorescent protein fused to other proteins o f interest is widely used in cell biology for 
studying their functions. But there are also some limitations in using GFP type proteins in 
labelling. They form aggregates inside the cells which causes toxicity. There are also some 
issues regarding their photostability as they photobleach upon extended excitation.88 In recent 
years a new class o f fluorophores which has shown great promise in cell labelling are QDs. 
QDs are ideal candidates for biological imaging because they have large extinction 
coefficients, large Stokes shifts, and high photostability.85 QD having different emission 
profiles can be excited using a single exciting source; this is a very useful property as it gives 
an opportunity to use QDs o f different colours in the same labelling experiment. But there are 
also some difficulties in using QD as biological labels. As their size increases after 
bioconjugation, it becomes more difficult for them to cross the cell membrane and they can 
also be cytotoxic.89
All these fluorophores have benefits as well as limitations which makes their use selective 










Endogenous proteins ++ + -
Clinical specimens ++ + -
Animals Ex vivo Ex vivo Transgene live
Primary tissues ++ + Transgene/virus
Live cells in culture Surface Surface ++
Multiple proteins at 
once
++ ++ -H -
Dynamic interactions +/- +/- ++
T urno ver/synthesi s - - +
Protein microarrays ++ + -
In gel fluorescence - - +
Western blot - + -
Major advantages Diversity o f Bright and Live cells and
properties photostable specificity
Major limitations Targeting in live cells Targeting and 
penetration
Ectopic expression
Improvements expected Generic conjugated Smaller, diversity Better properties,
primary antibodies o f properties generic sensors
Table 1.3 Different types of flurophores for biological labelling . Applicability ranges from 
most optimal (++) to generally not applicable (-), and (+/-) indicates applicable in some cases
1.5 Applications of QDs in Biological Imaging
1.5.1 Imaging of fixed cells and tissues
Imaging of fixed cells provides important data about the activities which are taking place 
within a cell or a heterogeneous cell population. QDs have been used in many fixed cell 
staining studies. For example, Bruchez et a/.80 labelled nuclear antigens and F-actin filaments 
using QDs of different colours in fixed mouse fibroblasts which were simultaneously excited 
with 363 nm light.
QDs are also used in fluorescence in situ hybridization (FISH) for mapping or detecting 
genomic sequences. FISH is a technique in which single stranded DNA, hybridized with 
targeted sequence(s) o f complimentary nucleic acid which is further detected by a probe like 
QDs or organic dyes. QDs were functionalized with DNA by using carbamate linkages and 
used for binding selectively Y chromosome in human sperm cells (Figure 1.22).60
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Figure 1.22 Fluorescence micrograph of in situ hybridization of red quantum (Amax= 609 nm, 
fwhm = 38 nm) dot probe(s) for the Y chromosome in human sperm cells (taken from Pathak et
a!.60).
Wu et a l 19 linked QDs to IgGs and streptavidin and these bioconjugates were used to label 
the cancer marker Her2 on the surface o f fixed and live cancer cells. They were also used in 
staining actin and microtubule fibers in the cytoplasm and in detecting nuclear antigens. The 
photostability between QDs (QD-608) and organic dyes (Alexa 488) was compared. It was 
found that under the conditions used in this experiment Alexa 488 had lost 50% o f it initial 
intensity even after 10 seconds, and after three minutes it had lost all its fluorescence (Figure 
1.23). In contrast the QD fluorescence intensity was never compromised.
Figure 1.23 Nuclear antigens were labeled with QD 630-streptavidin (red), and microtubules 
were labeled with Alexa 488 conjugated to anti-mouse IgG (green) [taken from Wu et a!.79].
QDs have been used also as cancer cell biomarkers. For example, Sukhanova et a/.90 prepared 
(CdSe/ZnS) QDs in which cysteine molecules are bound to the QD via sulfhydyl groups, a 
layer of poly(allylamine) polymer is bound to negatively charged carboxylate groups o f 
cysteine by electrostatic interactions to label MCF7r breast adenocarcinoma cells. In these
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QDs the amine groups o f the polymer are used to covalently attach anti-mouse polyvalent 
goat antibodies which recognise ^-glycoproteins (p-gp) overexpressed in membrane o f these 
cancer cells.
1.5.2 Live cell imaging
The availability o f probes for live cell imaging is very limited and QDs can make a 
significant contribution in this area. However, for better understanding o f the cell’s 
intracellular assembly it is important to cross the plasma membrane barrier. There are four 
methods to surpass the plasma membrane barrier: microinjection, non specific uptake, protein 
or peptide specific uptake and uptake induced by receptor-ligand recognition.91 
Chan and Nie58 covalently conjugated transferrin on mercaptoacetic acid-coated CdSe/ZnS 
QDs. They found that the QD-transferrin conjugates were taken up by cancer cells by 
receptor-mediated endocytosis. This work revealed that QDs retain their optical properties in
92vivo and have potential to be used as intracellular labels. Dubertret et al. achieved live cell 
imaging o f Xenopus embryo cells by microinjecting the PEG-coated CdSe/ZnS QDs having 
green emission into single embryo cells (Figure 1.24). Microscopic fluorescence imaging was 
utilized for real time monitoring o f cell lineage and differentiation. It was also found that the 
embry os exhibited normal growth even with the injection o f over 1 billion QD particles per 
cell.
QD ir^ection
F‘9ur?. V24 Quantum dot labelling of Xenopus embryos at different stages showing the 
specific intracellular localizations of the QDs (taken form Dubertret et al.52).
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Dahan et a l93 used antibody-bound red QDs for detecting plasma membrane glycine 
receptors (GlyRs) on neuronal cells (Figure 1.25). After formation o f QD-GlyR conjugate 
within synapatic and extrasynaptics domains, real time diffusion for single QD-GlyR was 
observed for more than twenty minutes.
Figure 1.25 QDs as a marker for GlyR localization in neurons QD-GlyRs (red) detected over the 
somatodendritic compartment identified by microtubule-associated protein-2 (green). Arrows 
ark clusters of QD-GlyRs located on dendrites (taken form Dahan et a l.93).
Lidke and co-workers94 used the peptide specific uptake approach for studying the 
intracellular structure o f human epithelial carcinoma cells. Preparation o f QDs -  EGF 
(epidermal growth factor) conjugate was done for labelling erbB (epidermal growth factor 
receptor). They observed receptor binding in real time with quantification o f binding and 
internalization.
1.5.3 In vivo animal imaging
For in vivo imaging a probe must contain a targeting m otif with high affinity for a specific 
tissue, and a fluorescent domain that emits light on binding to the target. The targeting 
domain must be modular so that any tissue could be imaged. There are also other 
requirements the probe must meet. It must minimize non-specific interactions, it must have 
long term stability and it should have a proper metabolism mechanism. QDs have large 
surface area which provides the possibility o f attaching many functional units for enhancing 
the binding.91
Akerman et a l 95 reported the first studies on in vivo animal imaging with QDs. CdSe/ZnS 
QDs with either green or red emission were given intravenously to mice. QDs were attached 
to lung targeting peptide and targeted to the lung vasculature. QDs were also linked with
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tumour homing peptides for targeting to tumour blood vessels. They coated QDs with peptide 
alone or with both peptide and polyethylene glycol (PEG) and they found PEG coating on 
QD prevents non-specific uptake. Peptide coated QDs were found excellent in targeting the 
vascular site without any aggregation.
In 2003 Kim et al.45 fluorescently imaged murine and porcine sentinel lymph nodes after 
intradermal injection o f near infra-red (CdTe)CdSe QDs. Injected QDs were phagocytosized 
by dendritic cells and then migrated to sentinel lymph node that could then be fluorescently 
detected even 1 cm under the skin surface.
QDs have also been used in tumour targeting and imaging. Gao et a l 96 succeeded in targeting 
and imaging human prostate cancer in nude mice. A nude mouse lacks thymus and functional 
immune system so it can be used in studying growth o f myeloma cells. They prepared QD 
probes conjugated to a prostate tumour specific antibody which were successful in targeting 
selectively human prostate tumours (Figure 1.26).
Figure 1.26. Imaging of QD-prostate-specific membrane antigen (PSMA) Ab conjugates in live 
animals harbored with C4-2 tumor xenografts. Orange-red fluorescoence signals indicate a 
prostate tumor growing in a live mouse (right)ffaken from Gao et al.96].
In response to stress and brain injuries astrocytes (macroglial cell types found in the brain) 
are activated, so they are considered an important key marker in detecting stress conditions in 
a cell. Maysinger et a l91 observed real time imaging o f astrocytes. For this study the GFAP- 
Luc (lucifrase) transgenic mouse was used in which the bioluminescent luciferase gene which 
will be expressed in the event o f oxidative stress. So in the event o f any stress or in response
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to foreign nanoparticles these mice will become luminescent. They used a range o f QDs and 
found the PEGylated QDs cause very little tissue damage as compare to other QDs.
1.5.4 Intracellular uptake of QDs
Like for other nanoparticles, intracellular delivery of QD depends upon their size and surface 
charge. There are specific and non-specific ways o f QD intracellular delivery. Micropipette 
injection, electroporation and biomolecule-mediated specific delivery are distinctive delivery 
methods,98 whereas endocytosis is a non-specific entry mode. Endocytosis is a transporting 
process by which macromolecules and small particles travel from the plasma membrane. It is 
a very important pathway for cells as they communicate with each other by using 
endocytosis. They also use endocytosis for supplying nutrients and generating immune 
responses. Endocytosis can be classified into phagocytosis (uptake o f large particles) and 
pinocytosis (uptake o f fluid and solutes). Phagocytosis is found in specialized membranes 
like those found in macrophages, monocytes and neutrophils. But pinocytosis is found in all 
mammalian cells.
QDs are commonly delivered to the cells by clathrin-mediated endocytosis which is the most 
common form of receptor-mediated endocytosis (Figure 1.27). In clathrin- mediated 
endocytosis the ligand binds to a specific cell surface receptor which is followed by the 
clustering o f ligand receptor complexes in coated pits (these are formed by assembly of 
cytosolic coat proteins among which clathrin is the main component). Then these coated pits 
forms intracellular clathrin coated vesicles by pinching off the plasma membrane. After 
clathrin depolymerises and proton influx acidifies the early formation o f endosomes takes 
place. In next step ligand is released from the endosomes.99
Figure 1.27 Clathrin-mediated endocytosis (taken from Khalil et al.99).
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There are several examples of QD delivery by receptor-induced endocytosis. For example, 
Chan and Nie58 conjugated transferrin to QDs by EDC coupling (see section 1.3.4.1), and 
found that transferrin mediated the endocytsosis o f the QDs. Lidke and co-workers94 used 
QDs -  EGF (epidermal growth factor) conjugates for labelling erbB (see section 1.5.2) and 
these QDs were also internalized by receptor-mediated endocytosis.
1.5.5 QD Cytotoxicity
The potential cytotoxicity caused by QDs is a key issue for in vitro and in vivo biological 
imaging applications. However, investigating and deciding whether QDs (in general) are 
toxic is challenging. Currently there are no standard methods for synthesising QDs and the 
organic coatings used to over-coat them are also highly variable. Another complication arises 
from the fact that cell systems used in each study are often very different. So it is hard to get 
a reasonable answer about their toxicity. It is generally accepted that there are two 
mechanisms by which QDs can be toxic: (1) by release o f heavy metals from the core o f 
nanocrystals like cadmium, selenium, tellurium etc. (2) by formation of reactive oxygen 
species (ROS).
The most documented and widely studied QDs for biological applications are made o f CdSe 
and CdTe. Cadmium is a class 1 carcinogen100 which affects DNA stability severely by 
stopping DNA repair mechanisms. Cadmium also induces oxidative stress by depleting 
naturally occurring antioxidants like glutathione (Figure 1.28). In cadmium-containing QDs 
release of cadmium ions is believed to be the primary mode o f cytotoxicity. Release of 
cadmium ions can be due to oxidation or due to the intracellular acidic environment. In 
general this type o f cytotoxity can be minimized by overcoating the Cd-containing cores with 
ZnS. Equally, if  the nanocrystal is properly protected by polymers or proteins the QDs are 
mostly non-toxic101 at the concentrations required for biological applications.
Because QDs are redox active nanoparticles they can generate ROS by energy or electron 
transfer to molecular oxygen. Generation o f small amounts o f ROS is sufficient to inhibit 
proliferation and induce differentiation in cells. It is also well known that at higher 
concentrations, ROS cause damage to cellular proteins, lipids, DNA and carbohydrates, and 
that it can cause apoptosis or necrosis.98,102 However, also in this case the type o f material 
torming the QD affects its toxicity.103 Moreover, the light source used and the irradiation 




biological applications the phototoxicity o f QDs is problematic, it can also be beneficial and 
be exploited medically (e.g. to kill cancer cells in photodynamic cancer therapy).
Ovidativc strips induces multiple changes in different cell organelles 
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Figure 1.28 ROS produced by QDs can induce organelle damage (taken from Maysinger et
al.98).








16 Thesis objectives and overview
The main objectives of this PhD thesis were:
To develop new strategies to label biomolecules with QDs.
• To investigate the biological activity o f molecules which are attached to QDs.
• To exploit QDs for novel biological applications.
Two aspects which this thesis research wanted to investigate and find answers for were:
® Site-specific labelling, is it important to maintain biological activity?
• QD large size and multivalency; are these properties beneficial or a problem?
In this thesis several new strategies for labelling various biomolecules on QDs are devised 
and the biological activity of the constructs is studied. Ni-NTA modified QDs are used for 
site specific labelling of the recombinant enzyme glutathione-S-transferase (GST) in Chapter 
2. In Chapter 3, the multivalency and hydrophobic nature of QDs are used to site-specifically 
attach an important immunostimulatory molecule, Kdo2-Lipid A, which is the main 
component of the outer membrane of E. coli and thus mimics this microbial pathogen. In 
Chapter 4, site-specific labelling strategies based on Ni(NTA)-His-tagged and multivalency 
are exploited to anchor a different number o f malaria surface protein 1 (MSP 1) molecules 
and thus develop valuable material to investigate and mimic the early events involved in the 
recognition and attachment o f the merozoite o f the malaria parasite Plasmodium falciparum  
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2.1.1 Metal-mediated labelling of histidine-tagged proteins
Proteins are widely used in genomics and proteomics. Production o f various 
recombinant proteins with affinity tags has increased exponentially over the years. 
Affinity tags are exogenous amino acid sequences having high affinity for specific 
biological or chemical ligands. Various affinity tags are used in protein production





His-tag 5-15 Purification under native or denaturing 
conditions
FLAG 8 Calcium-dependent, mAb-based 
purification
Streptag II 8 Modified streptavidin, elution with biotin 
analog
HA-tag 9 Influenza virus hemagglutinin tag, Ab- 
based purification
Softagl, Softag 3 13, 8 Recognized by polyol-responsive mAb
c-myc 1 0 mAb-based purification
T7-tag 11-16 mAb-based purification
S-tag 15 S-protein resin affinity purification
Chitin-binding domain 52 Binds only insoluble chitin
Thioredoxin 109 Affinity purification with modified resin
Xylanase 10A 163 Cellulose based capture, elution with 
glucose
Glutathione S-transferase 2 0 1 Glutathione or GST-Ab affinity
Maltose binding protein 396 Amylose affinity purification
Table 2.1 Affinity and solubility tags for recombinant proteins.1
The most widely used affinity tags are those having a variable number o f histidine 
residues, so-called His-tags. It has been estimated that in molecular biology more than 
60% of proteins are expressed with His-tags. 1 Purification o f His-tagged proteins is 
based on immobilized metal affinity chromatography (IMAC). IMAC is a purification 
technique in which a metal ion is complexed with an immobilized chelating agent for 
protein purification. Binding of the His-tag to the immobilised metal ions on the solid 




Figure 2.1 Schematic illustration of His tagged protein binding to a metal-chelated 
affinity support.
Transition metals commonly used as ions in IMAC are Cu(II), Ni(II), Zn(II), Co(II) 
and Fe(III). All these metals ions are electron pair acceptors and are Lewis acids. In 
the immobilised chelating agents, electron donor groups like sulphur, oxygen and 
nitrogen are present and coordinate with metal ions to form stable metal complexes. 
The remaining metal coordinating sites on the metal are occupied by water molecules 
and can be exchanged with electron donor groups from the protein like an histidine 
group. Adsorption of his-tag proteins to IMAC columns is normally accomplished at 
neutral or slightly basic pH to ensure that the imidazole nitrogen o f the histidine 
residue stays deprotonated .2 Hochuli et a l 3 was the first to use the metal chelator 
nitrilotriacetic acid (NTA) as an adsorbent in IMAC. NTA occupies four positions in 
the coordination sphere of the metal ion (Figure 2.2), e.g. Ni2+. The remaining two 
sites are available for selective protein interactions (i.e. with the His-tag). It has been 
found that Ni2+ binds very strongly to NTA; more strongly than to any other ligand 
previously used in IMAC .3





In several studies Ni-NTA derivatized nanoparticles and organic dyes have been used 
for site-specific immobilization o f his-tagged proteins.
The first study o f Ni-NTA mediated his-tagged protein conjugation to organic dyes 
was reported by Kapanidis et a l4 who attached the widely used cyanine fluorochrome 
to Ni2+-NTA moieties (Figure 2.3). These constructs were capable o f fluorescence 
labelling an His6-tagged derivative o f the transcriptional activator Catabolite 
Activator Protein (CAP) upon binding of Ni+ 2 ions to the NTA fragment. They found 
that compounds la  and lb  have relatively low affinity for the hexahistidine (His6) tag 
(Kd > 10 pM), whereas 2a and 2b have quite high affinity (Kd = 1 .0  pM for 2a; Kd = 
0.4 pM for 2b). All these compounds, however, had poor emission (fluorescence 
quantum yield < 0 . 1 ).
A B
Figure 2.3 Some fluorophores A = (Ni+2:NTA)i derivatives of Cyanine 3 (1a) and 
Cyanine 5 (1b); B =(Ni+2:NTA)2 derivatives of Cyanine 3 (2a) and Cyanine 5 (2b) used 
for protein labelling (taken from Kapanidis et al.4).
Lata et a l 5 designed even higher affinity recognition units for his-tagged proteins by 
exploiting the concept o f multivalent chelator heads (MCHs). In these constructs 
several NTA moieties (termed bis-, tris-, and tetrakis-NTA) were attached to a 
fluorescein dye (Figure 2.4). Interactions between these MCHs and polyhistidine 
(hexahistidine and decahistidine) tagged proteins were studied. It was observed that 
binding stability improves after increasing the number o f NTA moieties linked to 
fluorescein dye. The stronger binding was observed between the tris-NTA derivative 
and the His]0-tagged protein; Kd ~ 0.1 nM.
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Figure 2.4 Schematic of different scenarios of multivalency in Ni-NTA binding to 
polyhistidine-tagged proteins (taken from Lata e ta !.5).
• 2+The problem with these Ni-NTA dye conjugates is still that the paramagnetic N r  
ions strongly quench the fluorescence o f the dye (quantum yields < 0 . 1 ), limiting the 
practical applications o f these systems for biological imaging purposes. However, 
Lippard et al.6 overcame this problem and labelled His6-tagged extracellular proteins 
expressed on the outer surface o f HeLa and HEK 293-T cells using a different 
fluorescein-based dye which attached to a single Ni-NTA unit had a fluorescence 
quantum yield of ~ 0.7. Unfortunately the binding affinity was not as good (K^ = 1-20 
pM).
Ni-NTA modified nanoparticles have also been used in site specific labelling of
7 7proteins. Xu et al. used Ni-NTA modified magnetic (FePt) nanoparticles (less than 
10 nm in diameter) for binding, purifying and carrying His6-tagged green fluorescent 
proteins (GFP) (Figure 2.5). They found these magnetic nanoparticles have high 
surface/volume ratio and better solubility than micrometer-sized resins or beads used 
in IMAC, and provide a simple procedure to obtain pure GFP directly from the 
mixture of lysed cells in a matter o f minutes. The lowest concentration o f proteins that 




Figure 2.5 Ni-NTA-modified magnetic nanoparticles selectively bind to histidine-tagged 
proteins in a cell lysate (taken from Xu et a!.7).
In a different approach Lim and co-worker8 reported the encapsulation o f highly 
monodisperse magnetic (Fe2 0 3 ) nanoparticles inside micelles formed by a mixture of 
PEG and NTA-Ni modified phospholipids (Figure 2.6). This self-assembly approach 
which exploits hydrophobic interactions has the advantage o f requiring fewer 
synthetic steps.
i
Figure 2.6 Schematic illustration of the surface modification strategy of iron oxide 
magnetic nanoparticles with NTA-phospholipids and subsequent immobilization of 
histidine-tagged EYFP (taken from Lim et al.8).
Gold nanoparticles have also been attached to Ni-NTA units for site-specific labelling 
of his-tagged proteins. For example Abad et al, 9 prepared NTA-Co(II) terminated 
gold nanoparticles for the site-specific immobilisation o f his-tagged deglycosylated 
horseradish peroxidase (HRPrec) and ferredoxin-NADP+ reductase (FNR) (Figure 2.7).
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They found that bound to the gold nanoparticles these enzymes had 93-97% of the 
activity o f the free native enzymes; this is one of the few studies investigating the 
extent to which biological activity is preserved (critical aspect; vide infra).
E D C /N H S
ANTA-Co(II)
O
Figure 2.7 Reaction strategy showing the steps required for the construction of NTA- 
terminated nanoparticles for specific immobilization of His-tagged proteins (taken from 
Abad et al.9).
Lee et a l 10 used a very different approach for binding his-tagged proteins on 
nanoparticles. They found that in Ni/NiO core/shell nanoparticles the nickel surface 
itself provides a platform to bind the his-tagged protein effectively.
Finally, it is important to mention that it is possible to use non-metallic nanoparticles 
to achieve fluorescence site specific labelling o f proteins. For example, Kim et al.u 
described the preparation and characterization o f tetramethylrhodamine (TMR)- 
encapsulated silica nanoparticles and their functionalization with Ni-NTA. However, 
these constructs require many synthetic steps and the fluorescence characteristics o f 
TMR is compromised by the Ni-NTA surface-modification.
2.1.2 Glutathione-S-transferases
2.1.2.1 General
Glutathione-S-Transferases (GSTs; E.C.2.5.1.18) are a large super family o f enzymes 
found mainly in the cytosol, mitochondria and microsome . 1 2 ' 15 They play a major role 
in the detoxification of xenobiotic compounds. The most significant catalytic activity 
of GST is the conjugation o f the tripeptide glutathione (GSH) to electrophilic 
substrates, carcinogens and metabolites. This conjugation yields a more water soluble
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product which is then excreted, and thus GST acts as a detoxifying enzyme of 
endogenous and xenobiotic electrophiles. GSTs exist as soluble enzymes in virtually 
every living species examined, including plants and bacteria . 12 The soluble fonn o f 
GST exists as a dimeric protein with a monomer having a molecular weight o f 
approximately 28 kDa. Each monomeric unit has an active site composed o f two 
distinct functional regions: an hydrophilic G-site, which binds the physiological 
substrate glutathione (GSH), and an adjacent H-site which provides a non-polar 
environment for binding the electrophilic substrate (Figure 2.8 ) . 12 ,16  The G-site is 
highly specific for GSH and it is conserved between all GSTs. Here, the enzyme uses 
multiple hydrogen bonding interactions to bind and activate GSH. In contrast, the H- 
site is quite divergent so that it can bind various substrates. 1 2 ,1 7  GSTs are over­
expressed in myeloma cells causing resistance against chemotherapeutic agents used 
in cancer treatment. Consequently, they are promising therapeutic targets in 
anticancer therapy. GSTs isoenzymes are also over-expressed in neurodegenerative 
diseases, multiple sclerosis and asthma. There are two mechanisms by which GSTs 
cause resistance to anticancer drugs. In the first mechanism GST causes the direct 
detoxification o f xenobiotics using glutathione as a reducing agent. In second 
mechanism, GST causes the inhibition o f mitogen activated protein (MAP) kinase 
pathway, which is responsible for causing apoptosis o f cells. 18
Figure 2.8 Crystal structure of hGSTP1-1 homodimer. The G (Glutathione) site of one 
monomer faces the H (Substrate) site of its partner. This figure was drawn using PyMol
2.1.2.3 Catalytic activity of GST
GSTs are enzymes that participate in the purification o f xenobiotics and other 
carcinogenic compounds in living organisms by a GSH conjugation reaction. These 
reactions are of two types . 19
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1. Displacement reactions. In these reactions GSH displaces electron withdrawing 
groups such as halogens, nitriles and carboxylic acids.
2. Addition reactions. GSH is added to double bond structures or strained ring 
systems.
GST plays two basic functions to catalyse the modification o f a substrate: 1) it brings 
the substrate into close proximity to GSH by binding to both substrate and 2) it 
activates the GSH sulphur atom for nucleophilic attack . 12  
A general reaction for GST catalysis is:
GSH + RX g$T » HX + GSR
1-Chloro-2,4-dinitrobenzene (CDNB) is the universal electrophilic substrate for 
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Figure 2.9 Glutathione conjugation to 1-chloro-2,4-dinitrobenzene (CDNB).
2.1.2.2 GSTs from Schistosoma japonicum
Schistosoma japonicum  is a parasitic helminth worm that causes schistosomiasis. 
Schistosomiasis is parasitic disease infecting more than 275 million people worldwide 
which results in around 200 thousand deaths annually 20'21. Two isoenzymes found in 
S. japonicum are of 26 kDa and 28 kDa. Like other GSTs the 218 residues o f each 
subunit of the Sj26GST dimer form a small N-terminal a./P domain (residues 1-76), a 
shorter linker region (residues 77-84), and a larger a-helical C-terminal domain 
(residues 85-218). The Sj26GST dimer assembly creates a long (40 A) and narrow 
(approximately 6 - 1 0  A) inter-domain cleft. An essential catalytic residue is a tyrosine 
in position 7 (Figure 2.10) . 22 ' 23
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Figure 2.10 Crystal structure of the active site of sjGST. This figure was drawn using 
PyMol.
2.2 Motivation for the work
Currently, to conjugate QDs to biomolecules the QD surface is derivatized in such a 
way as to allow the attachment o f the biomolecules through a covalent bond, 
electrostatic or hydrophobic interactions. A typical biomolecule contains many 
residues capable o f forming covalent and non-covalent linkages with the QD. Thus, 
common problems associated with conjugating proteins to QDs in this way include 
non-specificity, irreversibility and limited control over the location and orientation o f 
the QD in the biomolecule. Because QDs are large (e.g. similar in size to a protein) 
the functionality o f the biomolecule cannot be taken for granted and must be proven 
experimentally. In most cases this has meant showing that molecular recognition with 
an appropriate partner does occur. However, biological activity may be more complex 
than this recognition, e.g. it may involve catalysing chemical reactions. In this 
Chapter we address these problems and issues by site-specific labeling o f an his- 
tagged GST on Ni(NTA)-modified CdSe/ZnS nanoparticles. GST represents a 
challenging and interesting target because it is an enzyme which requires dimerisation 





All chemicals were obtained from commercial sources and used as received. 
Cadmium oxide (CdO, 99.5%), tri-n-octylphosphine oxide (TOPO,99%), \n-n- 
butylphosphine (TBP, 97%), hexadecylamine (HDA, 98%), diethylzinc (ZnEt2 ,1 M in 
hexane), hexametyldisilathiane [(TMS^S 98%], thioctic acid , nickel(II)chloride, N- 
hydroxysuccinimide (NHS, 98%), A-A-bis(carboxymethyl)-L-lysine hydrate, 1- 
chloro-2, 4-dinitrobenzene and L- Glutathione were purchased from Sigma Aldrich. 
l-Ethyl-3-[3’-(dimethylamino)propyl]carbodiimide was purchased from Ademtech. 
Stearic acid (98.5%) was purchased from Fluka. Selenium powder (Se, 99.999%) was 
obtained from Alfa Aesar. BCA protein Assay kit was purchased from Pierce 
Biotechnology. Recombinant forms of S. japonicim  GSTs (histidine and untagged 
GSTs) were obtained from Anne Caniard and Dr. Dominic Campopiano from School 
of Chemistry, University o f Edinburgh.
2.3.2 Synthesis of CdSe and CdSe/ZnS QDs
Hydrophobic CdSe and core-shell CdSe-ZnS QDs were synthesised and purified 
adapting a previously reported procedure with some modifications. 24 
In a typical synthesis, CdO (0.013 g, 0.1 mmol) and stearic acid (0.254 g, 0.89 mmol) 
were loaded into a three-neck flask and heated to 225°C under N2 flow and stirring. 
Once the mixture was completely dissolved, it was allowed to cool to room 
temperature. Then, TOPO (3 g) and HDA (1 g) were added and the mixture was 
heated to 225 °C under N2 flow and vigorous stirring. At this temperature, 1 mL of 
freshly prepared TPB-Se solution (1 M) was quickly injected into the flask [tri-«- 
butylphosphine selenide (TBP-Se, 1 M)] was prepared in a N2 -filled glove box by 
shaking 0.08 g of selenium powder in 1 mL of TBP). Following injection the 
temperature was adjusted to -200 °C to promote nanocrystal growth for 5 h. Different 
aliquots were removed from this reaction mixture at different time intervals. On 
reaching the desired nanoparticle size, as determined by UV/vis and fluorescence 
spectroscopy the reaction mixture was cooled down to room temperature. The 
nanocrystals were then dispersed in chloroform and precipitated by addition of 
methanol. After centrifugation the supernatant liquid phase was removed. This
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procedure was repeated at least three times. The precipitates were combined and dried 
under a stream of N2 at room temperature.
For CdSe-ZnS QDs, on reaching the desired nanocrystal (CdSe) size, the temperature 
was lowered to ca. 100 °C to stop further growth. Then, the solution was heated to 
210 °C. At this temperature, 0.5 mL of the ZnS stock solution was slowly injected 
into the reaction pot [a ZnS stock solution was prepared in a N2-filled glove box by 
reacting (TMS^S (0.5 mL, 2.5 mmole) with ZnEt2 (3.5 mL, 3.5 mM in hexane) in 
TOP ( 6  mL)].The temperature o f the mixture was set to 100 °C and stirred for 2 hr. 
After cooling to room temperature, the nanocrystals were dispersed in chloroform and 
precipitated by addition o f methanol. After centrifugation the supernatant liquid phase 
was removed. This procedure was repeated at least three times. The precipitates were 
combined and dried under a stream o f N2 at room temperature.
2.3.3 Preparation of dihydrolipoic acid
Dihydrolipoic acid (DHLA) was prepared according to the method given by Uyeda et 
al.25 Thiotic acid (1.22 g) was dissolved in an aqueous solution o f NaHCC>3 (25 mL, 
0.25 M) and the resultant solution was cooled to 0 °C. NaBFL (0.9 g) was added and 
the temperature was maintained at ca. 5 °C with continuous stirring for about 2 hr 
under nitrogen. The reaction mixture was acidified with HC1 (3.3 M) to pH 1. The 
product was extracted with toluene (-30 mL) dried by adding MgSCL. The final 
product (Figure 2.11) was isolated as colourless oil and a *H NMR of the product was
obtained.
‘H NMR (250 MHz, CDC13) 8 /ppm: 2.90 (IH , m, H6), 2.69 (2H, m, H9), 2.37 (2H, t, 
H2), 1.89 (IH, m, 1/2H8), 1.80-1.40 (7H, m, H3, H4, H5, 1/2H8), 1.35 (IH , d, H7), 1.30 






Figure 2.11 DHLA with NMR numbering assignments
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2.3.4 Synthesis of water soluble quantum dots
The water-soluble DHLA-coated CdSe/ZnS QDs were prepared according to the 
method given by Mattoussi et a l 26 with some modifications. In a. typical reaction, 
stearic acid-coated CdSe-ZnS QDs (50 mg) and DHLA (50 mg) were mixed in DMF 
(15 mL). The solution was heated to 60-70 °C and stirred overnight. Then, potassium- 
tert-butoxide ( 1 0 0  mg) was slowly added to deprotonate the terminal lipoic acid 
groups. The nanoparticles were separated by centrifugation at (700 g ) and the 
supernatant liquid was discarded. The resulting QDs were dried under vacuum. The 
QDs were further purified by re-dissolving them in water and passing this solution 
through a 100 kDa microsep filter.
2.3.5 Modification of quantum dot surface by NTA and NTA- 
Ni2+ complex
AT/V-Bis(carboxymethyl)-L-lysine hydrate (NTA) (5 mg, 0.0132 mmole) was 
dissolved in 3 mL of HEPES (20 mM, pH 7.5). Activation of carboxylate groups o f 
the DHLA-coated QDs was performed by mixing the QDs (9 mg) in 1 mL o f EDC (3 
mM in HEPES) and 1 mL of NHS (3 mM in HEPES) with stirring for 30 min (this 
gives a QD concentration o f 3.5 pM). Then, 1 mL of NTA (4.4 mM) was added and 
the solution was stirred for 24 h. The resulting NTA-modified nanocrystals were 
purified using a Nanosep 100 kDa omega membrane filter (low protein-binding, 
modified polyethersulfone on polyethylene substrate). The Ni-NTA coated 
nanocrystals were prepared in the same way using the preformed complex, which was 
prepared by mixing of A,7V-bis(carboxymethyl)-l-lysine hydrate (NTA) (5 mg, 0.0132 
mmole) and NiCL (5 mg, 0.021 mmole) in 3 mL of HEPES (20 mM) with stirring for 
1 h . NTA and NTA-Ni2+ modified QDs were re-dissolved in phosphate buffer (600 
pL, 20 mM, pH 6.7) for specific immobilization o f enzymes.
2.3.6 Optical characterization
Optical absorption spectra o f the CdSe/ZnS QDs were measured using the Perkin 
Elmer Lambda 900 UV-vis spectrometer and the cuvettes had a path length o f 1 cm. 
Fluorescence studies were carried out with an Edinburgh Instruments FS900 
fluorometer using quartz cell. Excitation was at 350 nm with bandwidths o f 2 nm for 
excitation (unpolarised) and emission (unpolarised). Temperature was maintained at
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25 °C. The concentration o f the CdSe QDs was estimated using the method reported 
by Yu el a l21 in which equation I is used.
£ = 5857 (D) 2 '65 (I)
In equation I, D is the diameter o f the nanocrystal determined using the equation II 
D = (1.6122 x 1 0 'V 4- (2.6575 xlO'6)7.3 + (1-6242 x 10‘3)Z2 - (0.4277)2, + (41.57) (II)
where X is the position of the first excitonic absorption peak o f the QD. The 
concentration of the CdSe QDs samples was determined by using Lambert-Beer's law
A = scL
where, A is the first absorption peak intensity, £ is the extinction coefficient, L is the 
path length of the light beam, and C is the concentration o f the nanocrystal.
2.3.7 X-Ray photoelectron spectroscopy
XPS studies o f nanocrystals were performed by binding the QDs to self-assembled 
monolayers (SAMs) o f 1,6 hexanedithiol on gold surfaces. 28 Gold slides were 
chemically cleaned by immersing in a piranha solution (a mixture o f H2 O2 and 
conc.H2 S0 4  in 1:3 ratio) for 5-10 minutes. Caution: piranha solution reacts violently 
with organic materials and therefore must be handled with extreme care. Then, the 
slides were rinsed with water and methanol, dried under N 2 and used immediately. 
Monolayers of 1,6 hexanedithiol (10 mM) were prepared by immersing the cleaned 
gold strips into the methanol solution for about 15 h. Then SAM modified gold 
surfaces were rinsed with methanol and water. After this the SAM modified gold 
slides were transferred to a solution o f nanocrystals (CdSe and CdSe/ZnS, 3mg) in 
toluene (0.5 mL) for 6  h. X-ray photoelectron spectra were obtained with a VG 
Scientific Sigma Probe (UK) XPS system. The Al Ka anode X-ray source (hu =
1486.6 eV) was operated at 200 W and the take-off angle for photoelectrons was 37°. 
Samples were mounted with a spring clip. In a typical experiment, a few survey scans 
in the 100 to 1200 eV kinetic energy range were collected at a resolution o f 1 eV. 
hen, detailed scans o f 20-60 eV over a single feature were collected at a resolution of 
0.2 eV. During the measurements the pressure was 10"9-10’1 0 Torr.
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2.3.8 High-resolution transmission electron microscopy
High-resolution transmission electron microscopy (HRTEM) studies were conducted
on a JEOL JEM-2011 electron microscope operating at 200 kV. The samples were
prepared by depositing a drop o f a solution o f nanocrystals in pyridine onto a copper
28specimen grid coated with an holey carbon film and allowing it to dry.
2.3.9 Inductively coupled plasma - optical emission 
spectrometry (ICP-OES)
For ICP-OES samples were prepared by digesting QDs (40 pL) with 960 pL of 
concentrated nitric acid for 5 days. The samples were then diluted to 10 mL with 
Millipore water. Samples were analyzed by using Perkin Elmer Optima 5300 DV 
ICP-OES. The concentrations o f Cd, Se, Zn, S and Ni ions were estimated from 
calibration curves prepared by using standard solutions, from which the total amount 
of Cd, Se, Zn, S and Ni in the CdSe/ZnS QDs was estimated.
2.3.10 Protein binding studies by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE)
Protein binding studies were carried out by incubating 100 pL o f the corresponding 
QD (3.75 x 10'6 M) with 75 pL o f and H-GST and U-GST (1.09 mg/mL; 39 x 10'6 M) 
for 2.0 h at room temperature. Incubation was also performed in presence of salt 
(NaCl, 1M). The enzyme-QDs complexes were separated from the unbound enzyme 
molecules by passing this solution through a Nanosep 300 kDa Omega membrane 
filter (low protein-binding, modified polyethersulfone on polyethylene substrate). 
The retentate containing the QD-bound enzyme was treated with 175 pL o f a PBS 
solution of imidazole (0.5 M, pH=7.4) to release the enzyme. Retentate and filtrate 
fractions were analysed by SDS-PAGE .29 Similarly control retentate and filtrate 
fractions samples were prepared by using PBS.
Method for SDS-PAGE29
2x SDS-PAGE loading buffer was prepared by mixing Tris/HCL (1.5 M, pH 8.0, 1 
mL), glycerol (2 mL), bromophenol blue (0.05%), sodium dodecyl sulphate SDS 
(10%, 1.6 mL) and (3-mercaptoethanol (0.4 mL). Samples for SDS-PAGE were
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prepared by mixing loading buffer and sample in a ( 1 : 1 ) volume ratio followed by 
heating (100 °C, 5 min) and centrifugation (11,000 g, 2 min). A stand method was 
used for production o f acrylamide gel with running gel containing 15% acrylamide 
and stacking gel of 4% acrylamide. Briefly the running gel (acrylamide/ bis 
(29:1)15% w/v, SDS 0.1 w/v, TEMED 0.15 v/v and APS 0.1% w/v in Tris buffer 
(375 mM, pH 8 .8 ) was poured between the glass plate levelled and set at room 
temperature. The stacking gel (acrylamide/bis (29:1) 4% w/v, SDS 0.1% w/v, 
TEMED 0.15% v/v and APS O.lw/v in Tris buffer(125 mM, pH 6 .8 ) was then added 
and set at room temperature using a comb(mould) to produce the wells in finished gel. 
Gels were run in buffer (25 mM Tris, 192 mM glycine and 0.1% SDS, pH 8.3) at 200 
Vcm"'(180 mA). After the electrophoresis was finished, the gel was stained overnight 
in a mixture of 0.1% Coomassie Blue R-250, 40% methanol and 10% acetic acid and 
then destained in the same solution without Coomassie blue R-250.
2.3.11. Estimation of protein by bicinchoninic acid (BCA) 
Assay
Enzyme concentrations o f bound and unbound enzyme on QDs were calculated using 
a BCA™ protein Kit Assay (Pierce). BCA Protein Assay is a detergent-compatible 
formulation based on bicinchoninic acid (BCA). This assay is used for the 
colorimetric detection and quantification o f total protein in samples. A standard curve 
was prepared with different concentrations o f bovine serum albumin (BSA) and the 
samples were calibrated from the standard curve at 562 nm following the 
manufacturer’s instructions. In brief 100 pL of retentate and filtrate fractions were 
prepared as stated in SDS-PAGE studies. Then 2 mL of working reagent was added to 
the fractions (retentate and filtrate) and incubated at 37°C for 30 min. After 
incubation absorbance o f samples was measured at 562 nm in CARY 300 SCAN UV- 
vis spectrometer.
2.3.12 GST Activity Assay
The GST activity was determined spectrophotometrically by measuring the change in 
absorbance at 340 nm (s = 9600 M ' 1 cm ' 1 ) . 30 The solution for the blank assay was 
composed of potassium phosphate buffer (850 pL, 0.1 M, pH 6.5), l-chloro-2, 4- 
dinitrobenzene (50 pL, 40 mM) and GSH (100 pL, 80 mM). The solution for sample
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assay was composed o f potassium phosphate buffer (800 pL, 0.1 M, pH 6.5), 1- 
chloro-2 ,4 -dinitrobenzene (50 pL, 40 mM), GSH (100 pL ,80 mM) and GST 
solutions (50 pi, free and immobilized on QD-NTA-Ni+2). These GST solutions were 
prepared by adding 100 pL o f the phosphate buffer solution or QD (4 pM) to 75 pL 
of His-GST (1.14 mg/mL; 41 pM) and Untagged-GST (0.62 mg/mL; 22 pM). The 
absorbance was measured at 340 nm for five minutes (T = 20 °C).
One unit of GST activity is defined as the amount o f enzyme producing 1 pmol o f 
CDNB-GSH conjugate per minute under the conditions o f the assay, and was
•5 A
calculated using the formula:
Units/mL enzyme= (AA34o/min) x Total volume of Assay (in mL)
9.6 x Vol. o f enzyme used (in mL) 
where (AA34o/min)= A340 (Time 2) -  A340 (Time 1) / Time 2 (min) -  Time 1 (min).
2.4 Results and discussion
2.4.1 Synthesis and characterization of CdSe core and 
CdSe/ZnS Core/Shell QDs
QDs (CdSe and CdSe/ZnS) were prepared by using CdO as cadmium precursor 
instead of the extremely toxic, pyrophoric and expensive dimethyl cadmium 
Cd(CH3)2. At the temperature o f around 225 °C, CdO powder dissolved in stearic 
acid, and then on addition of TOPO and hexadecylamine generated colorless clear 
solutions. The formation o f CdSe nanocrystals took place immediately after injection 
of TBPSe as indicated by the formation o f yellow to dark red solutions. The resulting 
stearic acid-coated CdSe nanocrystals were collected and purified by a precipitation 
process induced by the addition o f MeOH. The precipitated nanocrystals were 
collected after centrifugation and redissolved in chloroform. This process was 
repeated several times to remove the free ligands and unreacted precursors. CdSe 
nanoparticles of different sizes were synthesised by changing the reaction time. The 
QD diameter and extinction coefficient were estimated by UV-Vis spectroscopy using 
equations I and II as given in experimental section, and the validity o f these 
expressions to calculate QD concentration was checked against ICP-OES data.
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For example a QD having Lmax = 620 nm has according to formulas I and II a 
diameter o f 5.6 nm and an extinction coefficient (s) of 564400.303 M ' 1 cm '1. For such 
QD, the theoretical number of Cd and Se atoms per QD can be calculated using the 
bulk density (5.665 g/cm3), formula weight o f CdSe, and volume o f a 5.6 nm 
spherical nanoparticle (equation III). This calculation estimates ca. 1600 Cd and Se 
atoms.
g 4 1cm 3 Im olCdSe , mol Cd atom s C datom s
5.665—=—x —u2.8 nm x    - x --------------- x N A x l --------------------= -1 6 3 9 ........................  I l l
cm3 3 1x10 nm 191.37g m olC dSe nanopartide
A 1.3 pM QD solution (according to the calculated extinction coefficient value o f 
5.64 x 105 M ' 1 cm '1, Table 2.2) gave a concentration o f Cd and Se of 0.942 mg/L (8.4 
pM) and 0.619 mg/L (7.8 pM) respectively after 250-fold dilution. Thus, the 
agreement between concentrations calculated using ICP and UV-Vis data is excellent. 
Figure 2.12 and Figure 2.13 shows the photoluminescence absorption and emission 
spectra of QDs of five different sizes. HRTEM images o f these QDs revealed that 
they are crystalline, spherical and monodisperse. Figure 2.14 shows the HRTEM 
image of CdSe QDs having the first absorption peak at 599 nm. It shows QDs with an 
average diameter o f 4.4 nm, and therefore UV-Vis and equation II provided a good 

















Figure 2,12 U.V-vis spectra of different CdSe nanoparticles (first absorption peak 
position: A= 564 nm, B = 575 nm, C= 592 nm, D= 599 nm, E= 620 nm).
Wavelength (nm)
Figure 2.13 Fluorescence emission spectra of four different CdSe nanoparticles 
(emission peak position after excitation at 350 nm: A = 585 nm, B = 600 nm, C = 614 
nm, D = 627 nm, E = 642 nm; Temperature = 25°C).
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Figure 2.14 HRTEM images of CdSe QDs with a 1st absorption peak at 590 nm.
Core/shell QDs were prepared by overcoating the CdSe nanocystals with ZnS which 
is an higher band gap material. Diethylzinc (ZnEt2 ) and bis(trimethylsilyl) sulfide 
((TMS)2 S) in TBP (tri-n-butylphosphine) were used as Zn and S precursors in this 
work. The temperature at which the ZnS was added and growth temperature was 200 
°C and 100 °C, respectively. These conditions avoided the self-nucleation o f ZnS and 
ensured that most o f the ZnS grew over the CdSe cores.3 1 The resulting stearic acid- 
coated CdSe/ZnS (core/shell) nanocrystals were purified by several steps o f 
precipitation-centrifugation (as in the synthesis o f the CdSe core QDs). As expected32, 
capping of CdSe core with ZnS shell increased the fluorescence o f these QDs. There 
was also a small red-shift in the position o f the first absorption peak (< 5 nm) and 
corresponding emission maximum (15-20 nm). This is due to the increase in size of 







Figure 2.15 U.V-vis spectra and fluorescence emission spectra of CdSe and CdSe/ZnS 
QDs (Excitation at 350 nm, Temperature = 25°C).
Figure 2.15 shows the typical photoluminescence absorption and emission spectrum 
of CdSe and CdSe/ZnS QDs illustrating these changes. After formation o f the ZnS 
shell, the size of QD increases. Figure 2.16 shows HRTEM images o f the CdSe/ZnS 
QDs with a diameter o f ~ 5.6 nm (compared to ~ 4.4 nm for the corresponding CdSe 
QDs; Figure 2.15). Since a shell o f ZnS measures 0.31 nm3 1 then an increase o f 1.4 
nm means that this particular QD had upto 4 monolayers o f ZnS. It has been shown 
that overcoating CdSe QDs with 4-5 monolayers provides the best results in terms o f 




Figure 2.16 TEM (a) images and HRTEM (b) images of CdSe/ZnS QD.
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2.4.2 Synthesis of water soluble QDs
The first step in the QD water solubilisation process was to prepare dihydrolipoic acid 
(DHLA). The DHLA was successfully prepared by reduction o f thioctic acid using 
sodium borohydride. 25 Then, CdSe/ZnS core/shell water soluble QDs were prepared 
by the ligand exchange method in which stearic acid on the QD surface was replaced 
with DHLA. Their optical properties were studied by UV-vis and fluorescence 
spectroscopy. For example a DHLA-coated CdSe/ZnS QD (QD-DHLA) with a first 
absorption peak at 561 nm (Figure 2.17) showed fluorescence emission maximum at 
598 nm (excited with 350 nm light, Figure 2.18). HRTEM images o f these 
nanocrystals revealed that they are spherical and monodisperse with a diameter o f ~ 
5.0 nm (Figure 2.19).
Wavelength (nm)
Figure 2.17 U.V-vis spectrum of water soluble QD-DHLA
Wavelength (nm)
Figure 2.18 Fluorescence emission spectrum of water soluble QD-DHLA (Excitation at 
350 nm, Temperature = 25°C)
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Figure 2.19 TEM (a) images and HRTEM (b) images of water soluble QDs
2.4,3 Modification of QD surface by NTA and NTA-Ni2+ 
complex
The surface modification o f DHLA-coated QDs with NTA-Ni was accomplished as 
shown in Figure 2.20. It involved the reaction o f DHLA-coated QDs with N,N- 
bis(carboxymethyl)-L-lysine hydrate (and its Ni2+ complex) using EDC and N- 
hydroxysuccimide as coupling agents in phosphate buffer solution. The position o f the 
emission band did not change upon attachment o f Ni-NTA units, and the 
photoluminescence intensity o f the Ni-NTA-capped QD (QD-DHLA-Ni(NTA)) was 
found to be ca. 85% that o f the metal free NTA-capped QD (QD-DHLA-NTA) 
(Figure 2.21). This is important because the paramagnetic Ni2+ was found to strongly 





H20  (20 mM HEPES, pH = 7.4)
Figure 2.20 Scheme for the Ni(NTA)-functionalization of QDs.
Wavelength (nm)
Figure 2.21 Pholuminescence spectra for CdSe-ZnS core-shell QDs coated with DHLA- 
NTA and DHLA-Ni(NTA) (Excitation at 350 nm, Temperature = 25°C)
The composition of the QDs was examined by X-ray photoelectron spectroscopy 
(XPS) and inductively coupled plasma-optical emission spectrometry (ICP-OES). The 
XPS spectra showed the main diagnostic peaks o f the coupling o f the NTA-Ni2+ units 
to the QD; a 2s peak at 400.1 eV due to N, and 2p3 and 2pl peaks at 857.1 and 874.1 
eV, respectively ,due to Ni2+ (Figure 2.22).
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B inding  energy  (eV)
B inding  energy  (eV)
Figure 2.22 X-ray photoelectron spectra highlighting the (A) N 1s and (B) Ni 2p 
transitions of the DHLA-Ni(NTA) coated CdSe-ZnS core-shell QDs.
The amount of Ni-NTA units per QD was estimated by ICP-MS. For example QDs 
with a fluorescence emission maximum at 610 nm contained around 16 Ni-NTA 
complexes on the surface.
2.4.5 Protein binding studies
GST from the helminth worm Schistosoma japónica (SjGST, 26 kDa monomer) was 
selected as our target enzyme because it is amenable to overexpress GST in E. coli as 
an hexahistidine(His6)-tagged construct and it is also well characterized .34 It is 
important to note that the His6-tag was genetically fused at the N-terminus. Site- 
specific attachment of GST to QDs was expected for the combination o f QD-DHLA- 
Ni(NTA) and HÍS6-GST (Figure 2.23). To assess the extent to which this is the case a
60
Chapter 2
series of protein binding study was carried out. Hexahistidine tagged GST (His6-GST) 
and untagged GST (U-GST) were added to solutions o f QD-DHLA-Ni(NTA), QD- 
DHLA-NTA, and QD-DHLA as stated in the experimental section. Nanosep 300 kDa 
Omega membrane (low protein-binding, modified polyethersulfone on polyethylene 
substrate) filters were used for isolation o f the enzyme-QDs bioconjugates. Filtration 
was carried out for 1 h under ultracentrifugation, which gave enzyme-QDs conjugates 
in the concentrate and unbound enzyme molecules in the filtrate.
Figure 2.23 Scheme illustrating the strategy used for the attachment of His6-GST on 
Ni(NTA)-functionalized QDs.
The non-covalent attachment o f His6-tagged and U-GST to the QD surface before and 
after derivatisation with Ni-NTA was analyzed by SDS-PAGE. A solution o f the QD 
or PBS (as control) was incubated with the corresponding enzyme for 2 h and passed 
through a Nanosep 300kDa centrifugal device. The retentate was redissolved in PBS 
buffer, and both retentate and filtrate were analyzed by SDS-PAGE. In the absence of 
the QD, His6-tagged and U-GST were found only in the filtrate. Several reports have 
shown that the DHLA-coated CdSe-ZnS core-shell QDs are capable o f binding his- 
Ugged proteins by coordination to Zn2+ ions at the nanocrystal surface .35 Our SDS-
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PAGE studies, however, did not find protein in the retentate (Figure 2.24). Lack of 
binding could be due to steric hindrance at the N-terminus location o f the His6-tag
94-preventing access to the Zn atoms o f the nanoparticle. In contrast, using the same 
experimental conditions (QD: protein ratio 1:8) the Ni-NTA-capped QDs 
immobilized both enzymes. However, there was more His6-GST than U-GST in the 
retentate (essentially no protein molecules were found in the filtrate), which is 
consistent with His-tag-Ni(NTA) recognition. Binding was also investigated in the 
presence of high salt concentrations. His6-GST binding to Ni-NTA-capped QDs was 
not affected by 1 M NaCl. In contrast, U-GST did not bind to the QDs under these 
conditions, which suggests it is predominantly electrostatic. Thus, high salt 
concentrations can be used to avoid binding o f untagged proteins while ensuring 
binding of the desired His-tagged target. The enzyme was easily released from the QD 
surface upon addition o f 0.5 M (pH 7.4) imidazole, which competes for the Ni2+ 
binding sites. Thus, decorating the surface o f the QD with Ni2+ complexes o f NTA 
seems a good approach for non-covalent reversible site-specific fluorescent labeling
of proteins, which can be used for instance if  carboxylate-functionalized QDs lacking
»2+ • • .
Ni ions fail. Potential advantages of attaching Ni-NTA units to QDs could be 
stronger interactions with the histidine tag (Kd ~ 10' 13 M ) 36 and less sensitivity to 
steric hindrance and surface properties by being further away from the nanocrystal 
surface.




Figure 2.24 SDS-PAGE of the retentate (R) and filtrate (F) after ultrafiltration through a 
Nanosep 300 kDa filter of His6-GST (a), U-GST (b), His6-GST incubated with QD (c) and, 
U-GST incubated with QD (d). Coomassie blue staining was used in this study.
R F R F R F R F
(a) (b) (c) (d)
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The loading capacity o f Ni-NTA QDs for His6-GST was estimated by BCA Assay. 
When Ni-NTA QDs (0.4 nanomole) were incubated with His6-GST (2.7 nanomole) it 
was found that all the GST molecules had been attached to the QDs, consistent with 
the SDS-PAGE studies. After decreasing the amount o f Ni-NTA QDs two-fold (0.2 
nanomole) only 1.4 nanomole o f His6-GST protein molecules were attached to the 
QD; the remaining were found unbounded. When the amount o f Ni-NTA QDs was 
decreased to 0.1 nanomole, only 0.27 nanomole o f enzyme was attached and no 
protein binding was observed when the amount o f Ni-NTA QDs was reduced to 0.05 
and 0.025 nanomole. Based on this it seems that under these conditions -7-8 
molecules of His6- tagged GST can be loaded on each QD. Since each QD had ~ 16 
Ni(NTA) complexes, this suggests that only 50 % is available for protein binding.
The maximum number (purely based on geometric close-packing considerations) of 
His6-GST molecules that can be loaded on each QD can be estimated using the 
equation IV .26
NHise = 0.65 (R2 3 -  R i3)/RP 3 ...................................(IV)
where R\ is the core-shell nanocrystal radius with the lipoic acid and Ni-NTA cap and 
R-i ~R\ + 2RV is the radius o f the core-shell QD plus bound protein molecules. In this 
expression it is assumed that protein molecules are close-packed as spheres around a 
central QD and it takes account o f the filling factor o f hard spheres and adjusts the 
volume ratios by a factor o f 0.65.26 We have estimated the values for R\ = Rq + 
d(ZnS) + d(lipoic acid ) + d(Ni-NTA) -  45 A (where Rq is QD core radius and d is the 
distance of ZnS shell, lipoic acid and Ni-NTA from the core radius) and R2 -100 A 
{Rp = 28 A where Rp radius o f monomeric protein) , 37 We have found theoretically ~ 
27 His6-GST molecules can be loaded per nanocrystal. For dimeric GST the 
theoretical maximum of GSTs per QD would therefore be ~13. O f course this 
theoretical estimate is subject to errors as the shape o f the protein may not be 
spherical, nonetheless it gives a rough idea o f the .number o f protein molecules which 
can be packed around the QD, and is consistent with the experimental result o f 7-8 
protein molecules per QD.
The protein purification efficiency of the Ni-NTA-capped QDs was also investigated by 
incubating E. coli cell lysates containing His6-GST for 2 h. Remarkably, pure 
fluorescently labelled GST was obtained simply by ultracentrifugaton of this mixture
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(Figure 2.25 B). Thus, by using the Ni-NTA-capped QDs it is possible to purify and 
fluorescently label histidine tagged proteins in a single step. Current methods for 
efficiently purifying and fluorescently labelling His-tagged proteins need various 
labour-intensive and expensive steps, such as conjugation o f NTA derivatives on 
support materials or the preparation o f suitable magnetic nanoparticles for purification 
purposes, followed by the attachment o f fluorescent tags. Another construct suitable for 
one-step protein purification and site-specific labelling was recently developed and 








14.4 cell lysate pure QD-bound
His-tagged GST
Figure 2.25 SDS-PAGE studies of the cell lysate containing His6-GST (lane 2) and 
proteins released from the Ni-NTA-coated QDs treated with PBS containing 0.5 M 
imidazole (lane 3) and supernatant (lane 4) after ultracentrifugation. Lane 1 is the 
molecular weight marker. (B) Images of the cell lysate after ultracentrifugation and of 
the pure QD-bound His6-tagged GST
2.4.6 Enzyme assay for biological activity
TChloro-2,4-dinitrobenzene (CDNB) was used as a substrate for measuring the 
catalytic activity o f bound GST on QDs. The GST-catalysed reaction o f GSH with 
CDNB produces a dinitrophenyl thioether which can be conveniently detected 
spectrophotometrically at 340 nm .30 His6-GST (14.93 U/mL) and U-GST (8.52 U/mL) 
were incubated with the same concentration o f Ni-NTA-capped QD. It was found that 
His6-GST retains full activity (14.7 U/mL) after binding to the QD, whereas non­
specific binding of U-GST on QDs leads to ca. 70-75% of its activity (6.27 U/mL, 
Figure 2.26 A). Our hypothesis is that the ability o f the His6 -tag to control the 
position of the Ni-NTA-capped QD relative to the GST active site is responsible for
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preserving the activity o f the enzyme. The X-ray crystal structure o f SjGST23 shows 
that the N terminus, which is where the His6-tag was placed, is ca. 25 A away from 
the essential catalytic residue Tyr7 (Figure 2.26 B). On examining the distribution of 
positively and negatively charged residues it was found that there are positive and 
negative regions close to the active site. These are sites where in the absence o f the 
His6-tag non-specific electrostatic binding could occur, disrupting the enzyme 
activity. From the SDS-PAGE studies we estimated that ~25-30 % o f the U-GST is 
captured non-specifically by the QD (see Figure 2.24), which suggests the activity 
found is only due to the unbound U-GST.
(A)
figure 2.26 (A) Activity of His6-tagged GST (N-terminal) and untagged GST in the 
presence of Ni-NTA coated QDs. Conditions: [GSH] = 8 mM, [CDNB] = 2 mM in PBS (pH 
6.7), T = 25 °C. The QD alone did not have any activity. (B) X-ray crystal structure of the 
SjGST homodimer highlighting the catalytically crucial Tyr7 residue in red, and the N- 




2.5 Summary and Conclusion
In summary, in this study it was shown that Ni-NTA-coated QDs provide a 
straightforward method to, in one step, purify and fluorescently label proteins in a 
process that is reversible by addition o f a competing ligand for His-tag. By using 
these Ni-NTA-coated QDs it is possible to purify and label the N-terminal His6-GST 
which was impossible using QDs with carboxylates at the surface. Moreover, it was 
found that Ni2+ provides a docking site which helps to precisely orient the fluorescent 
nanoparticle on the protein surface, and that as a result, GST retained its activity. The 
use of His-tags has been broadly adopted in the molecular biology and biochemistry 
communities, and therefore this specific conjugation strategy should enable 
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In Chapter 1 various strategies for making water-soluble QDs were discussed. In 
Chapter 2, we applied the ligand exchange method to make water-soluble QDs with 
the ability to site-specifically label proteins as requirement for retention o f biological 
activity. This chapter deals with using hydrophobic interactions and amphiphilic 
biomolecules for making bioactive hydrophilic QDs. Moreover, it investigates for the 
first time the extent to which the large size and multivalent nature o f the resulting 
QDs can be useful for novel biological applications, specifically to mimic pathogens 
and elucidate how they interact and are processed by the immune system.
3.1.1 Hydrophobic-hydrophobic interactions for making 
biocompatible QDs
In 2002, Dubertret et al}  used hydrophobic-hydrophobic interactions to synthesise 
water-soluble QD-filled micelles. Phospholipids like l,2-dipalmitoyl-sn-glycero-3- 
phosphoethanolamine-N-[Methoxy (polyethylene glycol](mPEG-200 PE) and 1,2 
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) were used to encapsulate 
hydrophobic CdSe/ZnS QDs. In these amphiphilic polymers the hydrophobic part 
interacts with TOPO and other hydrophobic molecules on the QD surface and the 
hydrophilic part imparts water solubility.
In another interesting approach Osaki et a l 2 conjugated amphiphilic saccharides to 
CdSe QDs. These compounds have four alkyl chains and eight saccharide moieties 
(cellobiose, lactose, maltose or maltoheptaose) attached on opposite sides o f 
calix[4]resorcarene. The four alkyl chains provided a site for hydrophobic association 
with TOPO on the QD surface while the hydrophilic saccharide units provided 
aqueous solubility to the assembly.
Recently Peng3 encapsulated CdSe/ZnS QDs with the amphiphilic alginate natural 
polymer (Figure 3.1). It was based on the hydrophobic interactions between the QD’s 
TOPO molecules and the octyl chain o f alginate. These interactions result in phase 
transfer of hydrophobic QDs from organic solvents to aqueous solutions via the 
hydrophilic backbone (i.e. alginate).
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Fig. 3.1 Schematic drawing of CdSe/ZnS QDs encapsulated by amphiphilic alginate 
surfactant. (Taken from Peng et al.3).
3.1.2 Lipopolysaccharide (LPS)
3.1.2.1 Brief History of Endotoxins
Endotoxins are the compounds which cause “endotoxic” or “septic” shock .4 Eugenio 
Centanni was an Italian pathologist who in 1894 extracted endotoxin from Salmonella 
typhi and other Gram-negative bacteria and which he called “Pirotoxina” because of 
its fever-inducing pyrogenic properties. 5 Centanni described at the time endotoxin as 
ubiquitous to many bacterial genera (pathogenic and non-pathogenic), and an agent 
which induces potent immune responses. In 1950 the chemical identity o f endotoxin 
as lipoploysaccharide (LPS) was established, and in late 1970’s the physical and 
biological properties o f LPS were confirmed scientifically . 6 Chris Gallones and co­
workers found lipid A (see below) as the active centre responsible for the endotoxic 
properties of LPS. They found lipid A to be the toxic and pyrogenic material which 
induces local Schwartzman reaction (skin lesions) . 7
3.1.2.2 Architecture of LPS
In LPS there are three different domains/regions which determine its properties. These 
are the O-polysaccharide or O chain containing repeating sugar units which are 
species-specific, the strain-specific core polysaccharide and the structurally-diverse 
lipid portion termed as lipid A (Figure 3.2) . 8 Lipid A is the very hydrophobic and
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endotoxically active part o f LPS. The polysaccharide core region is covalently 
attached to lipid A and has an inner and outer core region. The inner core contains a 
high proportion o f unusual sugars such as 3-deoxy-D-manno-octulosonic acid (Kdo) 
and L-glycero-D-manno-heptose (Hep) while the outer core contains more common 
sugars such as hexoses and hexosamines. The polymer o f repeating saccharide 




Fig 3.2 (a) Electron micrograph of Escherichia coli. (b) Schematic representation of the 
location of lipopolysaccharide (LPS; endotoxin) in the bacterial cell wall, (c) 
Architecture of LPS. (d) Primary structure of the toxic centre of LPS; the lipid A 
component . GlcN, D-glucosamine; Hep, L-glycero-D-manno-heptose; Kdo, 2-keto-3- 
deoxy-octulosonic acid; P, phosphate. (Taken from Beutler et ai. ).
3.1.2.3 O-polysaccharide / O-region
This region contains between one and eight glycosyl residues which differ between 
strains in terms o f sugars, sequence, chemical linkage, substitution, number o f sugar 
units and ring forms utilized. As a result the O-region leads to limitless diversity; 
hundreds of serotypes have been observed for Gram negative bacteria. Moreover, the 
chain can contain between 0 and 50 subunits. In fact a single organism will produce a 
range of these lengths due to incomplete chain synthesis. In smooth type Gram- 
negative bacteria the O-region is the outermost part of their outer membrane, 
therefore it is a major antigen targeted by host antibody responses. This is a reason 
why sometimes the O-region is called the O antigen .9 For some organisms, these O-
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polysaccharide / O-region is essential to escape from lytic action by the compliment 
complex (i.e. survival in host serum) o f the host. It also shields bacteria from 
numerous antibiotics.
3.1.2.4 Core polysaccharide
LPS structures have less variability in the core part than in the O-polysaccharide 
region. The outer core o f LPS is generally more variable and is made up of common 
hexose sugars such as glucose, galactose, N-acetyl galactosamine and N-acetyl 
glucosamaine. The inner core is less variable and consists of more unusual sugars, 
particularly Kdo and heptose, which are a-bound to the carbohydrate backbone o f 
lipid A. Acinetobacter and Burkholderia cepacia LPS are exceptions in this regard in 
that they have a 2 keto-D-glycero-D-talo-actonic acid (Ko) instead o f Kdo. The Kdo 
domain is very important for bacterial viability. It always contains negatively charged 
substituents (such as phosphate groups). The core polysaccharide has an important 
role in modulating the endotoxin activity o f lipid A. Typically, the bond between the 
lipid A and the first Kdo residue is easily hydrolyzed at pH <4.4, releasing the core 
form lipid A .9,10
3.1.2.5 Lipid A
The term lipid A is referred as the lipid domain o f the LPS molecule. In 1985, it was 
found that lipid A is the part o f LPS responsible for its endotoxic activity.
Lipid A consists o f a P-1,6 linked diphosphoryl-D-glucosamine (D-GlcN)
disaccharide with phosphate groups at positions C-l and C-4’ and up to seven 
hydroxylated fatty acid residues in ester or amide linkages (Figure 3.3). In some 
bacteria additional negatively and positively charged moieties such as
phosphoethanolamine (PEtN), 4-amino-4-deoxy-L-arabino-pyranose and D-




Fig 3.3 Structure of Kdo2-lipid A. (Taken from Sasaki et a!.12).
3.1.2.6 Mode of endotoxin action
The mammalian innate immune system senses pathogen associated molecular patters 
(PAMPs; evolutionary conserved, pathogen-derived motifs which the host uses to 
discriminate self from non-self) using a range o f pattern recognition receptors (PRRs), 
among which the Toll-like receptors (TLRs) are particularly important. 13 In the case 
of LPS, it is widely accepted that the Lipid A unit activates TLR4 on the extracellular 
side of the membrane o f cells o f the innate immune system. There is also widespread 
agreement that TLR4 is required for signalling through a group o f Toll/interleukin-1 
receptor (TIR)-adaptors (TIRAP (also known as Mai), MyD8 8 , TRIF and TRAM ) . 14 
However, it is known that other receptors are involved in LPS-induced cell activation 
and that these form receptor clusters. LPS binding protein (LBP), CD 14, MD2, the 
macrophage scavenger receptor (SR-A) and P2 leukocyte integrins CD llb/CD 18 
have been shown to participate in LPS-induced cell activation . 15 It has been shown 
that both CD14 and CD11/18 are capable o f initiating signals to cell, resulting in 
phagocyte activation, bacterial internalization (phagocytosis, endocytosis), and the 
activation of bactericidal defences. 16 These complex binding/signalling events then 
lead to the production and release o f cytokines and various other effects which result 
in the killing and clearance o f the invading pathogen (Figure 3.4). However, the 
biologic importance o f LPS internalization and its relationship to signalling are
73
Chapter 3
disputed, and it is also not clear if  the aggregation state affects the mode of
17internalization and signalling.
Release of cytokines etc.
Fig 3.4 Mode of interaction of LPS with immune cells.
3.1.2.7 Role of LPS derivatives in vaccine technology
Vaccines are the best weapons for combating infectious diseases but for many o f 
these diseases effective vaccines are yet to be developed. For example, vaccines are 
needed for parasitic diseases like HIV, malaria and tuberculosis which kill over 5 
million people per year. Vaccines are also urgent for diseases like hepatitis C, 
shigellosis, respiratory synctitial virus, dengue fever, schistosomiasis and influenza . 18 
Finding an effective vaccine requires not only an antigen but also an immune 
potentiator (adjuvant) and a delivery system . 19 The role o f the adjuvant is to trigger 
early innate immune responses, which then lead to the generation o f robust, long- 
lasting adaptive immune responses. The list o f adjuvants which are already in use in 
vaccines or in clinical trials includes mineral salts (e.g. alum which is aluminium 
hydroxide),emulsions and surfactant-based formulations (e.g. MF59), organic 
particulate-based delivery vehicles (e.g. liposomes), microbial derivatives (e.g. 
LPS/MPLA), whole.cells and cytokines (e.g. dendritic cells, IL-1 2 ), saponins (QS-21) 
and CpG oligos. 19 All these adjuvants have significant limitations, and thus finding 
new adjuvants and delivery systems has become a major target and bottleneck in the 
development o f new and more effective vaccines. Moreover, it has been suggested 
that the combination o f delivery systems, immune potentiators and isolated antigens 
will be required for optimal immune responses. 19 LPS derivatives like
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monophosphoryl lipid A (MPLA, Fig. 3) are strong candidates to become the first 
approved adjuvant for widespread use since alum . 19 However, the stimulatory effects 
of MPLA (and LPSs) rely on a complicated sequence o f events which involve a range 
of proteins as stated in the previous section (3.2.1.6). These events have not been 
structurally characterised in live cells or in vivo, and are likely to differ for each 
chemically different LPS. For example, it is interesting that MPLA generates 
clinically useful immune responses with only 0 . 1  % o f the inflammatory toxicity o f 
LPS. This could be due to structural changes (e.g. having only one phosphate ester) 
inducing subtle changes in the molecular interactions with these proteins . 20 Thus, 
attachment of LPS derivatives to QDs could lead to exciting results.
3.1.2.8 LPS and septic shock
Immune responses to LPS also play a key role in sepsis and septic shock, which is the 
most common cause o f mortality in intensive care units worldwide . 2 1 Sepsis is a 
harmful and damaging response from bacterial infection and when sepsis causes life- 
threatening low blood pressure, this condition is called septic shock. Several peptides 
natural and synthetic bind and block LPS activity by exploiting electrostatic and H- 
bonding interactions e.g. polymyxin B, defensins, buforin, lactoferricin B and 
magainin.21 The prototype is polymyxin B (PMB), for which the K& of the PMB-LPS 
complex has been estimated to be 1 pM . 22 But due to PMB toxicity it is only used in 
topical applications and extracorporeal removal o f endotoxins. Since many new 
nanomaterials can potentially bind to LPS investigating the immune responses to LPS 
when is attached or interacting with nanoparticles is becoming increasingly important.
3.1.3 Nano/microparticle containing LPS
Because of its high toxicity LPS cannot be used directly for immunization in humans. 
Thus, some researchers have started to investigate if the toxicity o f LPS can be 
reduced by encapsulation inside polymer micro/nanoparticles.
Murillo et a 1. 23 encapsulated a hot saline antigenic extract (HS) from Brucella ovis (B. 
ovis) in poly-e-caprolactone (PEC) microparticles. This vaccine was tested against B. 
ovis and B. abortus infection in mice. It was found to induce high amounts o f IFN-y 
(peptide responsible for activation of T-helper 1 [Thl] immune cells) and IL-2 
(growth factor for all immune cells) but low quantities of IL-4 (peptide responsible
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for activation and growth o f T-helper 2 [Th2] immune cells) suggesting a combined 
Thl/Th2 cellular response. Subcutaneous and oral vaccination protected mice against 
B. ovis infection. Free HS or empty polymer microparticles did not produce any
protective effect against brucellosis.
Recently in another study Gantrez ® (poly(methyl vinyl ether-co-maleic anhydride, 
MW 200,000) nanoparticles were used to deliver the B. ovis’s LPS for effective 
vaccination against anaphylactic shock. LPS o f B. ovis co-encapsulated with 
ovalbumin (OVA) were used as model allergen inside nanoparticles. They 
demonstrated that these modified nanoparticles can induce high level o f IL-10 
(peptide which suppress inflammatory reactions) thus showing highly interesting 
adjuvant properties for immunotherapy .24
In another study LPS functionalized iron oxide nanoparticles were used for antibody 
detection purposes. The iron oxide nanoparticles were functionalized with LPS from
B. abortus by adsorption. Variation in magnetic relaxation in these particles was 
related to their hydrodynamic volumes and measured using an A.C. susceptometer. 
The changes in relaxation frequencies for the LPS functionalized nanoparticles was 
used as a proof o f attachment o f LPS on the nanoparticle surface. When these LPS 
functionalized nanoparticles were mixed to the biological sample (serum) for 
detection of Brucella antibodies, it led to particle size increases o f 25-35%, which 
were consistent with antibody binding. The antibody detection limit was found to be 
0.05 pgm L "1 . 25
3.1.4 Liposomal preparations of lipid A
Liposomal preparations containing Lipid A have also been prepared with the intention 
of reducing the immunogenicity o f this biomolecule for use in vaccine therapy.
The first liposome containing Lipid A was prepared by Schuster et al.26 in 1979. The 
Lipid A used was isolated from Shigella flexneri LPS. They demonstrated that when 
one adjuvant (liposome) served as the carrier for the other adjuvant (lipid A) then the 
combination resulted in enhanced antibody formation against Lipid A in rabbits. They 
also confirmed that the liposome alone do not trigger any detectable immune 
response. In another study the biological activity o f LPS and lipid A from Salmonella 
Minnesota encapsulation within liposomes was studied. The liposomes formed were 
used to activate peritoneal macrophages which initiate both innate and cell mediated
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immunity. It was found that in vitro the liposomal LPS was 100-1000 fold less potent 
inducing IL-1 (a peptide which induces and promotes inflammatory responses) and 
TNF (a mediator o f inflammatory responses) that LPS alone. 27 Similarly, in another 
study Neissera meningitis LPS was incorporated into a liposome and 1000 fold 
decrease in the endotoxin activity was observed . 28 Dijkstra et a / . 28 proposed that a 
direct interaction of Lipid A with appropriate plasma membrane components is 
necessary to trigger the biological response efficiently. Insertion o f LPS into liposome 
can prohibit this interaction leading to less immunological activity.
In an interesting study the circumsporozite protein (CSP, a major malaria parasite 
surface protein during the sporogonic cycle) from Plasmodium falciparum  was 
encapsulated inside a liposome made up o f LPS. These immunogenic liposomes were 
used in phase I human preclinical studies, in which it was found that these 
immunogenic liposomes containing this malaria antigen cause very strong specific 
humoral immunity without any acute toxicity .29
3.1.5 Fluorescent sensing for phosphorylated peptides 
/proteins
Protein phosphorylation is widely involved in switching enzymatic activity and 
signalling transduction cascades o f living cells. As a result the development o f 
molecular probes which can selectively recognize phosphorylated proteins and 
enzymes has become an important target.30
Recently, artificial receptors containing dinuclear complexes have been found useful 
in recognizing and sensing phosphorylated proteins. This is because they exploit 
metal-ligand interactions which are stronger and more effective for phosphate 
binding/recognition in aqueous medium than other more commonly used interactions 
like hydrogen bonding and electrostatic interactions.3 1 Zinc complexes which use 
dipicolylamine (DPA) as metal binding ligand have been proven to be particularly 
effective, providing association constants of around 107 M ' 1 in water.32,33 
For example receptor 1 (Figure 3.5) combines the phosphate binding ability o f the Zn- 
DPA units with the fluorescent properties o f the anthracene unit to form 1 : 1  
complexes with phosphorylated peptides with affinities ranging from 104 to 106 M ’, 
depending on the peptide sequence. Binding o f the phosphate species to the receptor 
is reported by an increase in fluorescence (~ four-fold increase). It was found that the
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fluorescent enhancement was due to a three-stage assembly process (Figure 3.6): 1) 
binding to the first Zn(II), 2) phosphate binding and 3) binding o f the second Zn(II) 
ion. Importantly, this sensor has excellent selectivity for the phosphorylated peptides 
over other common biologically relevant anions like chloride, inorganic phosphate 
and carboxylate.33
4 N 0 3-
Figure 3.5 Molecular structure of an artificial phosphate receptor/sensor (1).
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Figure 3.6 Mechanism of fluorescent enhancement and PET quenching. 
(Taken from O'Neil et.al.31)
Smith et a/.31 used the same principle for sensing bilayer membrane surfaces 




We have found that this anthracene-derived bis(Zn2+-DPA) complex, and related Zn- 
DPA complexes can act as effective pattern recognition receptors for LPS sensing 
purposes via recognition o f the anionic phosphate esters within lipid A.34 Recently, 
Smith at a l3S have reported that as a result o f this latter property these complexes 
selectively target the surface o f bacterial cells.35
3.1.6 Multivalency and its importance in biological systems
The ‘valency’ o f a molecule or particle is the number o f groups of the same type 
which this compound possesses. Thus, multivalent species are those which carry 
several groups o f the same type. Many biological systems are activated through 
simultaneous binding o f groups or ligands to the same receptor, and thus it has 
become an important tool for designing drugs and vaccines. Because the interactions 
which arise from multivalent species are stronger than those of monovalent species 
they are very useful in initiating signal transduction responses. An interesting example 
of multivalency is the adhesion of the influenza virus to the surface o f the bronchial 
epithelial cells, which results in binding of several copies o f the virus hemagglutinin 
(HA) to sialic acid (SA) on bronchial epithelial cell (Figure 3.7).36 
Gold nanoparticles have been used as a scaffold for exploiting multivalency of 
biomolecules (pathogenic polysaccharides) with the intention o f developing more 
effective synthetic vaccines. For example, Manea et al,37 prepared sacccharide- 
functionalized gold nanoparticles by self assembly as fully synthetic analogs o f type 
A Neisseria meningitides antigens for protection against meningitis. They found that 
these nanoparticles were two times more antigenic than the corresponding oligomeric 







Figure 3.7 The influenza virus attaches to cells by interaction of trimeric hemagglutinin 
(HA3i shown as protruding cylinders on the virus) with sialic acid (SA, shown as caps 
on the cells).
3.2 Motivation for the work
In Chapter 1 we have described why colloidal quantum dots (QDs) have become 
important materials in biology as alternatives to traditional organic dyes. But there are 
important differences between conjugation o f biomolecules to QDs and organic dyes. 
An important one is that QDs are multivalent and have a size comparable or larger 
than most biomolecules, and therefore, a relatively large number o f biomolecules can 
be conjugated to a single QD. Indeed, it is difficult to ensure that a single biomolecule 
is attached to them and is still biologically active. In most cases proving that the 
biomolecule is active has meant showing that molecular recognition with an 
appropriate partner does occur. However, this is not enough proof and biological 
activity may be more complex than this e.g. it may involve catalysing chemical 
reactions with specific efficiency or coupling molecular recognition with signalling 
events. Studies which have investigated this aspect reported both loss and 
preservation o f biological activity.38"41
We considered that the nanometer-size and multi valency o f QDs could be particularly 
useful to mimic and study how biomolecules and/or a combination of biomolecules in 
the proximity o f each other behave and interact with cells, tissues, organs etc., 
possibly more so than to study the behaviour o f biomolecules which may require 
being in isolation (focus so far in QD labelling of biomolecules). In Chapter 3 E. coli
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LPS is attached to QDs by hydrophobic interactions so that it could mimic the surface 
of Gram negative bacteria and therefore be useful model materials to investigate how 
pathogens interact and are processed by the immune system (Figure 3.8). The 
interaction of LPS with the QD and o f the QD-LPS conjugates with cells o f the 
immune system is investigated, as are the immune responses generated in vivo and in 
vitro.







All chemicals were obtained from commercial sources and used as received. 
Cadmium oxide (CdO, 99.5%), tri-n-octylphosphine oxide (TOPO,99%), tri-n- 
butylphosphine (TBP, 97%), hexadecylamine (HDA, 98%), diethylzinc (ZnEt2 ,1M in 
hexane) and hexametyldisilathiane [(TMS)2S 98%], were purchased from Sigma 
Aldrich. Stearic acid (98.5%) was purchased from Fluka. Selenium powder (Se, 
99.999%) was obtained from Alfa Aesar. E. coli LPS (Kdo2-lipid A) was obtained 
from Avanti Polar Lipids. The Purity o f E. coli LPS (Kdo2-lipid A) was checked by 
gel electrophoresis (DOC-PAGE) in Dr. Dominic Campopiano lab from School of 
Chemistry, University o f Edinburgh. This material is a mixture o f 6 LPSs from E. coli 
strain WBB06 which is deep rough. The hydrophobic CdSe/ZnS QDs were prepared 
as described in Chapter 2, the results presented here were obtained with QDs which 
had the first absorption band at 628 nm, and a maximum emission peak at 642 nm 
with excitation at 350 nm. BCA protein Assay kit was purchased from Pierce 
Biotechnology. The in vitro and in vivo biological studies were performed by Dr. Tom
A. Barr and Martin Krembuszewski in the laboratory o f Prof David Gray, School o f 
Biological Sciences at the University o f Edinburgh.
3.3.2 Synthesis of QD-LPS Micelles
QD-LPS micelles were prepared using two different methods (Method A and B). 
Method A. Hydrophobic QDs (1.5 mg, 0.36 nanomole) were combined with pure 
Kdo2-lipid A (E.coli LPS) (200 pi, 43 pM) and sonicated for 1 min. LPS 
functionalized nanoparticles forms a suspension after sonication. The suspension was 
kept for 4 h at room temperature to ensure the formation of micelles by hydrophobic 
interactions. This suspension contained both empty micelles and those containing 
QDs, the empty micelles were removed with ultracentrifugation cycles (5x60 min) at
11,000 g. The micelle containing QDs formed a pellet while the empty micelles 
stayed suspended. The successive supernatants were discarded and the final QD- 
micelles were resuspended in 250 pi of water, which gives a QD concentration of 
0.089x1 O'6 M (according to ICP-OES studies).
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Method B. As above but using 2.5 mg of QD (0.6 nanomole) and 250 \iL o f 430 pM 
LPS (1 mg/mL). This method gives a final QD concentration o f 0 .31xl0 '6 M. 
(according to ICP-OES studies).
3.3.3 Synthesis of QD-PC/PEG-PE Micelle
QD-PC/PEG-PE micelles were prepared according to a recently published 
procedure.42 In a 5 mL round-bottomed flask, 100 pi o f a chloroform solution of 
hydrophobic QD (2 mg in 100 pi of chloroform; 5 pM) and 50 pi chloroform 
solutions o f l,2-dipahnitoyl-sfl-glycero-3-phosphoethanolamine-N-
methoxy(polyethylene glycol)-2000] (ammonium salt) (2 mg in 50 pi o f chloroform; 
15 mM) and l-palmitoyl-2-oleoyl-5,n-glycero-3-phosphocholine (PC) (1 mg in 50 pi 
of chloroform; 26 mM) were mixed together. The flask was left open at room 
temperature for 3 h in a fume hood to slowly evaporate the chloroform solvent. Any 
remaining chloroform was removed under vacuum using a rotary evaporator to form a 
thin film. The flask containing the QDs was then heated in water bath set to 80°C for 
30 s, after which 250 pi o f doubly deionized water was quickly added. Addition of 
water forms a suspension containing both empty micelles and those containing QDs. 
Large aggregates were removed by two centrifugation cycles at 11,000 g and empty 
micelles were removed by centrifugation cycles (2 x 45 min) at 300,000 g. The 
micelles containing QDs formed a pellet while the empty micelles remained in 
suspension. The successive supernatants were discarded and the final QD-PC/PEG-PE 
micelles were resuspended in water.
3.3.4 Transmission Electron Microscopy (TEM)
High-resolution transmission electron microscopy (HRTEM) studies were conducted 
on a JEOL JEM-2011 electron microscope operating at 200 kV. The samples were 
prepared by depositing a drop of a solution o f nanocrystals in pyridine onto a copper 
specimen grid coated with an holey carbon film and allowing it to dry.




For ICP-OES samples were prepared by breaking down the QDs (40 pL) with 960 pL 
of concentrated nitric acid for 5 days. The samples were then diluted to 10 mL with 
Millipore water. Samples were analyzed by using Perkin Elmer Optima 5300 DV 
ICP-OES. The concentrations o f Cd, Se, Zn, S ions were estimated from calibration 
curves prepared by using standard solutions, from which the total amount o f Cd, Se, 
Zn, S in the CdSe/ZnS QDs was estimated.
3.3.6 Dynamic Light scattering (DLS)
DLS data was obtained on a Malvern’s Zetasizer Auto plate sampler (APS) equipped 
with 50mW 830nm Single-mode fibre laser. A 384-well microplate was used as 
sample container and 45 pL o f sample was used for each study. Because the solute 
was CdSe/ZnS, the reflective index was set to 2.50. Typically, the experiment was 
carried out for 3 runs o f 2 minutes each, and analyzed using the “number” (first-order) 
Multimodal Size Distribution.
3.3.7 Fluorescent sensing and quantification of LPS 
molecules on QD micelle by anthracene-derived bis(Zn2+-  
DPA) complex
Fluorescence studies were carried out with an Edinburgh Instruments FS900 
fluorometer. Excitation was at 380 nm and 500 nm with bandwidths o f 2 nm for 
excitation (unpolarised) and emission (unpolarised). U.V-vis studies were measured 
using the Perkin Elmer Lambda 900 UV-vis Spectrometrer and the cuvettes had a 
path-length o f 1 cm.
QD-LPS and QD-PC/PEG-PE micelles were titrated with increasing concentrations of 
anthracene-derived bis(Zn2+-DPA) complex {1} in HEPES (20 mM, pH 7.5). For 
each concentration o f 1 a fluorescence spectrum was obtained in the presence and 
absence of the QD micelles. The QD-LPS micelle attached to 1 were separated from 
the unbound molecules o f 1 by passing these solutions through a Nanosep 100 kDa 
centrifugal device.These solutions were then treated with EDTA (15 mM) to release 
the anthracene-(DPA) 2  ligand (Filtrate 1 in Figure 3.16).Retentate containing the QD- 
LPS-bound molecules o f 1 were also treated with EDTA to release the anthracene- 
(DPA)2 ligand from the QD-LPS micelles, and then passed through a Nanosep 100 
kDa Omega membrane filter (Filtrate 2 in Figure 3.16). Both filtrate fractions were
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analysed by UV-vis and the concentration of anthracene-(DPA)2 was calculated from 
the extinction coefficient o f 1 in the presence o f EDTA (15 mM) at 260 nm (e = 
32,500 L • mol"1 • cm"1) in HEPES (20 mM, pH 7.5).
3.3.8 In-vitro Studies
3.3.8.1 Cell culture
The J774A.1 macrophage/monocyte cell line was obtained from the European 
Collection o f Cell Cultures (ECACC). Cell cultures were grown at 37 °C in a 
humidified atmosphere o f 5% CO? in 30 mL of complete medium (Isocove’s 
Modified Dulbecco’s Modified Medium (IMDM) , containing phenol red, L- 
Glutamine (2 mM), Penicllin/Streptomycin (50 U/mL) (Pen/strep) and 5 % Foetal 
Calf Serum (FCS)). Cells were grown to confluence after which they were removed 
from the culture flask via gentle scraping and then resuspended in complete medium. 
Cell viability was determined using Trypan blue (0.1% solution) exclusion. Cells 
were adjusted to a suspension of 2.5x105 cells mL-1 in medium and used for the 
subsequent experiments.
3.3.8.2 Preparation of bone marrow-derived dendritic cells (BMDCs)
C57BL/6 mice at 6 weeks o f age were bred at The University o f Edinburgh animal 
facility. Bone marrow cells were cultured in RPMI 1640 medium, containing phenol 
red, L-Glutamine (2 mM), Pen/Strep (50 U/mL) , 10 % FCS and 20 ng /mL of 
Granulocyte-monocytes colony-stimulating factor (GM-CSF). The DC culture 
medium was replaced every 2 days to replenish GM-CSF and remove non-adherent 
cells. Cells were harvested by gentle aspiration on day 7 and then were used as 
immature DC for in vitro assays.
3.3.8.3 Cytokine Assay
In a 96 well-plate, 100 pL o f BMDCs or J744 Macrophages in IMDM medium 
(2.5xio5 cells mL“1, 25,000 cells per well), 50 pL of IMDM medium and 50 pL o f the 
QD solutions (15 nM), LPS (250 nM) or PBS alone were incubated for 16 h 
(macrophages) or 24 h (BMDCs) at 37 °C in an humidified atmosphere o f 5% C 0 2. 
Cultures were performed in triplicate in a final volume o f 200 pL (100 pL cells, 50 pL 
compound and 50 pL PBS). An additional group of cultures were set up with the LPS
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inhibitor polymyxin B (final concentration 250 pM) instead of PBS. The same studies 
were simultaneously carried out with ten-fold serially diluted samples. After 24 h, 
supernatants were harvested by centrifuging plates at 400g for 3 min. and gently 
removing medium from cells. Supernatants were then frozen at -20°C until used. 
Cytokine (IL-6) was quantified by capture ELISA. Plates were coated overnight with 
50 pi (10 pg/mL) IL-6 capture antibody (clone MP5-20FS, BD Pharmingen, UK). 
The following morning plates were washed with PBS/Tween 20 (0.05%) (Sigma 
Aldrich) and non-specific binding blocked with 2% bovine serum albumin (BSA). 
Samples (and recombinant cytokine for standardisation at 20 ng/mL to 9.8 pg/mL) 
were then applied to the plate. Following a lh  incubation at RT, plates were washed 
three times with PBS/Tween and a detection antibody (biotin labelled MP5-32C11, 
BD Pharmingen) added. Following a further 1 h incubation at RT and washing, 
streptavidin-alkaline phosphatase was added to the plates. Plates were again incubated 
and washed and then 50 pL (1.35 x 10‘4 M)p-nitrophenyl phosphate (PNPP) substrate 
added to the plate. Optical density at 405 nm was measured and cytokine 




C57BL/6 mice at 6-8 weeks of age were bred at The University o f Edinburgh animal 
facility. For intraperitoneal (i.p) vaccination with the DNP-OVA antigen, four groups 
of animals (n = 5 per group) were injected into the peritoneal cavity with:
• a 200 pi solution containing a single dose of 100 pg o f DNP-OVA (20 pL, 5 
mg/mL) co-administrated with QD-LPS nanoparticles (40 pL, 235 nM, 95 
pmol) in PBS (140 pL);
• a 200 pi solution containing a single dose o f 100 pg of DNP-OVA (20 pL, 5 
mg/mL) co-administrated with LPS (40 pL, 43 pM, 4 pg) in PBS (140 pL);
• a 200 pi solution containing a single dose o f 100 pg of DNP-OVA (20 pL, 5 
mg/mL) co-administrated with 180 pL PBS.
For subcutaneous (s.c.) vaccinations with the DNP-OVA antigen, animals (n = 5) 
received a single dose o f 100 pg of DNP-OVA antigen (20 pL, 5 mg/mL), co­
administrated with E. coli LPS (10 pL, 43 pM, 10 pg) and 70pl PBS, emulsified
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with 100 pL of incomplete Freund’s Adjuvant (IFA), with 100 pL injected in each 
flank. Statistical analysis was performed by using GraphPad, Prism, version 4.0b.
3.3.9.2 Analysis of serum DNP-OVA antigen-specific antibodies
Blood was collected via the dorsal tail vein at 7 day intervals. Samples were allowed 
to coagulate by overnight incubation at 4°C. Serum was separated from coagulated 
blood by centrifugation at 13,000 g for 3 min and stored at -20°C for later analysis. 
Antigen-specific IgG titers were analyzed by ELISA.
Plates were coated with 50 pL DNP-BSA antigen (10 pg/mL) per well at 4°C 
overnight. The following morning the plates were washed with PBS/Tween and 
blocked using PBS with 2% BSA (100 pL). Serum was diluted (1:10) in the blocking 
buffer and added to the plates. After 2 h incubation at room temperature, plates were 
again washed and incubated with 50 pL o f detection antibodies (Polyclonal Goat- 
mouse IgG streptavidin-alkaline phosphatase conjugate, 1:2500 dilution, anti-mouse 
IgGl alkaline phosphatase conjugate, 1:2000 dilution and IgG2c alkaline phosphatase 
conjugate, 1:1000 dilution) for 2 h. Following the incubation 50 pL (1.35 x 10-4 M) p- 
nitrophenyl phosphate (PNPP) substrate was added and the plates were read at 405 
nm. End-point antibody titre was determined by extrapolating the dilution which gave 
an OD of 0.2 for the titration curve.
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3.4 Results and discussion
3.4.1 Synthesis and characterization of CdSe/ZnS Core/Shell 
Nanocrystals
The hydrophobic CdSe/ZnS QDs were prepared as in Chapter 2. These QDs are 
coated with stearic acid - a  non-toxic naturally produced fatty acid commonly used in 
pharmaceuticals and cosmetics. The high-resolution TEM image shows a spherical 
QD particle with a diameter o f ~ 5.8 nm (Figure 3.11). A chloroform solution o f these 
QDs (2.5 pM) was prepared and gave a concentration o f Cd and Se o f 0.878 mg/1 (7.7 
pM) and 0.507 mg/1 (6.4 pM) respectively after 250-fold dilution by ICP-OES. The 
concentration o f Zn was found to be 0.95 mg/1 (14.6 pM). This gives ~ 770 Cd atoms, 
640 Se atoms and ~ 1460 Zn per QD. The number o f Cd, Se, Zn and S atoms per QD 
was calculated theoretically using the bulk densities and formula weights o f CdSe and 
ZnS, as described in Chapter 2, section 2.4.1). Based on this calculation spherical 
particles of ZnS with diameters of 5.8 and 4.4 nm should contain 2594 and 1134 Zn 
atoms respectively. Similarly a spherical particle o f CdSe with a diameter o f 4.4 nm 
would contain ~ 770 Cd atoms. Taking all this results into account we can estimate 
that the CdSe/ZnS QDs used in this study have a CdSe core o f 4.4 nm and a ZnS shell 
of 1.4 nm. The position o f the first excitonic peak for these QDs appeared at 628 nm, 
and the fluorescence emission maximum was 642 nm (Figures 3.9 and 3.10).
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Figure 3.10 Fluorescence emission spectrum of CdSe/ZnS nanoparticles (Excitation at 




Figure 3.11 High-resolution transmission electron microscopy (HRTEM) image of 
several CdSe-ZnS QDs (a), fast Fourier transform (FFT) of the QD inside the box (5.72 x 
5.72 nm) (b) and corresponding inverse FFT (IFFT) image, (c) EDX spectra of these QDs 
(d).
3.4.2 Synthesis of QD-LPS Micelles
Hydrophobic CdSe-ZnS QDs were attached to pure E. coli LPS (Kdo2 lipid A, Figure 
3.12). In these QDs hydrophobic chains o f stearic acid (~ 2 nm long) provide sites for 
strong interaction with the six hydrophobic chains o f this LPS (-1.5 nm long). QD- 
LPS micelles were prepared by mixing the hydrophobic QDs with excess o f pure 
Kdo2-lipidA by self assembly o f the biopolymer chains around the hydrophobic core 
of the QD. We investigated the effect o f biopolymer-to-QD ratio and we found that 
higher yields and smaller aggregates are obtained with higher ratios, presumably 
because the extra LPS prevents the formation of less water-soluble conjugates and the 
hydrophobic chains o f QD from interacting with each other. Dynamic light scattering 
(DLS) studies revealed that using a LPS:QD molar ratio o f 200:1 there are 
predominantly QD-LPS micelles which are between 11 and 15 nm in diameter in 
solution (Figure 3.14). This result correlates nicely with the size o f the QD and Kdo2 
lipid A. The core-shell nanocrystal has a radius o f 2.9 nm, stearic acid is 2 nm long 
and Kdo2-lipid A is ~ 3 nm long (Figure 3.13). If we consider that the QD at the point 
of interaction with the LPS chains has a radius o f 4 nm as suggested by the DLS 
results, and that LPS has a surface area o f 2 nm2 based on the dimensions o f Kdo2- 
lipid A43, then the maximum number of LPS molecules that at single QD can hold in 
its 200 nm2 surface is -100. As one might expect there are also a small percentage of 
larger particles, presumably due to the formation of clusters containing more than one 







Figure 3.12 Gel electrophoresis of the LPS used in the study. 39 K56-2 is the LPS from  
the B. cenocepacia parent strain K56-2 which has smooth LPS (O-antigen); SAL-1 is a 
mutant K56-2 strain which produces deep-rough LPS. Both of these are modified with 
Ara4N on the lipid A core 4’ phosphate. Kdo2-lipid A is LPS from an E. coli mutant 
strain WBB06 which is deep rough and commercially available from Avanti Polar 
Lipids. Silver Staining was used in this study.
Figure 3.13 Schematic diagram of the self-assembled QD-LPS micelle, illustrating the 
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Figure 3.14 Size distribution (dynamic light scattering) of QD-LPS (LPS = Kdo2-Lipid A).
3.4.3 Fluorescent sensing of LPS by anthracene-derived 
bis(Zn2+-DPA) complex
QD-LPS and QD-PC/PEG-PE micelles were titrated with increasing concentrations of 
1 (Figure 3.5) in HEPES (20 mM, pH 7.5) (Figure 3.15). In the presence o f QD-LPS 
micelles the fluorescence o f 1 is increased (Figure 3.15 A). In contrast, the 
fluorescence of 1 did not change in the presence o f QD-PC/PEG-PE micelles (Figure 
3.15 A). 1 selectively binds dianionic phosphate groups in QD-LPS. This result is 
consistent with the results obtained by Hamachi and coworkers33 in which similar 
enhancement in the fluorescent intensity o f 1 was observed after binding to 
phosphorylated peptides. It is also consistent with recent studies in our group in which 
1 was found to be an effective pattern recognition receptor for Kdo2-lipid A.34 Also 
recently, Smith et a l 44 have found that 1 selectively targets and fluorecescently labels 
the surface o f bacterial cell walls via recognition of the anionic phosphate esters o f 
LPS. At the same time the emission of QD in QD-LPS and QD-PC/PEG-PE micelles 
was quenched by the 1, presumably because 1 absorbs strongly at 380 nm (excitation 
energy used). However there was no QD quenching found when the excitation 
wavelength was 500 nm (Figure 3.15 B). From ICP-OES studies QD concentration in 
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Figure 3.15 Fluorescence titration of Control [(HEPES buffer (20mM, pH =7.5)], QD-LPS 
and QD-PC/PEG-PE micelles using 1. A= Region for emission of zinc (Il)-dipicolylamine 
complex in blank, QD-LPS and QD-PC/PEG-PE micelle (Excitation at 380 nm; 
Temperature = 25°C), B= Region for emission of CdSe/ZnS QDs in QD-LPS micelle and 
QD-PC/PEG-PE micelle (Excitation at 500 nm; Temperature = 25°C).
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3.4.4 Quantification of LPS molecule on QD micelle
Theoretically a maximum of 100 LPS molecule can be accommodated per QDs. The 
actual number o f LPS molecules per QD was determined by passing the QD-LPS 
treated with 1 through size-exclusion filters; unbound 1 passes through the filter, 
whereas bound to QD-LPS it does not. Since the UV spectrum of 1 and anthracene- 
(DPA)2 ligand are different, the filtrate was treated with EDTA (15 mM) to release 
the anthracene-(DPA ) 2  ligand (Filtrate 1 in Figure 3.16). The retentate s containing 
the QD-LPS-bound molecules o f 1 were also treated with EDTA to release the 
anthracene-(DPA) 2  ligand from the QD-LPS micelles, and then passed through a 
Nanosep 100 kDa (Filtrate 2 in Figure 3.16). Both filtrate fractions were analysed by 
UV-vis and the concentration o f anthracene-(DPA )2  was calculated from the 
extinction coefficient o f 1 in the presence of EDTA (15 mM) at 260 nm (e = 32,500 L 
• mol'1 • cm '1) in HEPES (20 mM, pEI 7.5). The QD-LPS micelles used in this study 
captured ca. 130 molecules o f this phosphate binding 1. Because each Kdo2-lipid A 
has two dianionic phosphate ester groups, we estimate that these QDs therefore carry 
around 65 LPS molecules each.
—• — 15 uM anthracene-(DPA)2
Wavelength (nm)
Figure 3.16 UV-vis spectra of 1 in HEPES (20 mM, pH 7.5) after addition of EDTA (15 
mM) to release anthracene-(DPA)2 from 1 (closed squares; 15 pM) and mixtures 
containing 1 (15 pM) + QD-LPS (50 nM). The molecules of 1 which did not bind to QD- 
LPS are in filtrate 1 (solid circles; 8.5 pM) and those which did bind to QD-LPS in filtrate
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2 (solid triangles; 6.5 hM). The control QD micelles (coated with PEG-PE or PC/PEG-PE 
mixtures) did not bind 1 (open squares).
3.4.5 In vitro studies
3.4.5.1 Activation of immune cells
The immunostimulatory activity o f the LPS-loaded QDs was evaluated with J774 
macrophages and bone marrow-derived dendritic cells (BMDCs) from wild-type mice 
(data not shown).Controls we used were PBS, uncoupled Kdo2-lipid A and 
phosphatidylcholine (PC) and n-poly(ethyleneglycol) phosphatidylethanolamine 
(PEG-PE) coated QDs.1
This involved quantifying IL-6 production by Enzyme linked immunosorbent assays 
(ELISA) (Figure 3.17). Increased IL-6 production was observed in both J774 
macrophages and BMDC cultures subjected to QD-LPS conjugates stimulation than 
that achieved with LPS alone. J774 macrophages in the resting state released 1.85 
ng/mL of IL-6 into the culture media during incubation for 12 h, whereas the cells 
markedly increased IL-6 production, up to 41.5 ng/mL and 2.4 ng/mL upon exposure 
to 250 nM LPS alone and LPS in the presence o f the LPS inhibitor polymyxin B 
(PMB) respectively. IL-6 production by macrophages treated with 1.5 nM QD-LPS 
(prepared by method B; LPS content = 97.5 nM based on 65 LPS molecules per QD), 
was even greater; 64.1 ng/mL o f IL-6 and suppressed to 0.02 ng/mL in the presence 
of PMB. So the activity o f LPS attached to QD is greater than alone. The increase in 
immunostimulatory activity seems substantial; 35 ng/mL of IL-6 are released by cells 
stimulated with 0.45 nM QD-LPS (prepared by method A; QD: LPS content ~ 30 nM 
based on 65 LPS molecules per QD) was only slightly smaller than with 250 nM LPS 
alone. Moreover, more IL-6 is released with 0.15 nM QD-LPS (prepared by method 
B: LPS content = 10 nM based on 65 LPS molecules per QD) than with 250 nM LPS 
alone.
The fact that release o f cytokines was strongly inhibited by the LPS antagonist 
polymyxin B (PMB), and that control QDs (QDs coated with PC and PEG-PE) lacked 




mm QD-LPS Method B (- PMB) 
□  QD-LPS Method B (+ PMB) 
■■LP S
Figure 3.17 Cytokine IL-6 production by J774 macrophages. (IL-6 release from  
macrophages treated with QD-LPS. At 1/10 dilution; [QD-LPS]Method a  = 0.45 nM; [QD- 
LPS]Method b  = 1.5 nM; [LPS] = 250 nM; [control QD] = 2.5 nM. PMB is the LPS inhibitor 
polymyxin B; [PMB] = 250 pM . Control = phosphate-buffered saline (PBS), pH 7.4. The 
control QD is coated with PC and PEG-PE instead of Kdo2-lipid A. Incubation time = 12 
h.
3.4.6 In vivo studies
3.4.6.1 Analysis of serum DNP-OVA antigen-specific antibodies
Immunoglobulin G (IgG) is an antibody which protects against bacterial toxins. IgG is 
the most prevalent immunoglobulin (Ig) isotype in serum and is present also in 
extravascular spaces.44 The formation o f complexes o f an antigen and IgG activates 
the complement system (a pathway which causes the lysis o f bacteria) and facilitate 
phagocytosis by immune cells. IgG is also the primary circulating Ig produced after 
reexposure to an antigen (secondary immune response). Vaccination with 100 pg 
DNP-OVA (20 pL, 5 mg/mL) co-administrated with QD-LPS (40 pL, 235 nM, 95 
pmol) had total IgG titers about 3-fold higher than that o f the mice co-administrated 
with LPS (40 pL, 43 pM, 4 pg) and 52-fold higher than animals vaccinated with 
DNP-OVA antigen alone (Figure 3.18). Moreover, co-administration o f QD-LPS 
micelles generated 2-fold greater response than the vaccination with incomplete 
Freund’s adjuvant - a  gold standard in adjuvant potency. IgG production in animals
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vaccinated with antigen and hydrophobic QDs (40 pL, 6.8 pM, 340 pmol) increased 
with time; this may arise from the ability o f the QD to capture LPS but further studies 
are necessary to elucidate the origin o f the adjuvant properties o f this QD. Secondary 
challenge (boosting) with 100 pg DNP-OVA (20 pL, 5 mg/mL) resulted in a robust 
increase in antibodies secretion at day 7 after second administration o f DNP-OVA 
antigen, indicating the acquisition o f immunological memory to this particular 
antigen. Noticeably similar titres o f antibodies production after secondary challenge 
were recorded in all tested animals except animals vaccinated with the antigen alone.
- E -  Q D -L P S
DAYS AFTER IMMUNIZATION /BOOSTING 
Figure 3.18 Total IgG class antibody production in mice.
3.5 Summary and Conclusion
We have demonstrated that the nanometer-size and multi valent nature o f QDs which 
enables multiple biomolecules to be attached to a single QD can lead to higher 
activity in vitro and in vivo than that obtained when the biomolecule is isolated. The 
biomolecule attached was pure Kdo2 Lipid A, a pathogen associated molecular pattern 
coating the surface of the outer membrane o f E. coli. Like in E. coli the LPS 
molecules are held by hydrophobic interactions. We have tested the ability o f these 
QD-LPS to bind and activate cells o f the immune system with LPS receptors like
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macrophages and dendritic cells. This requires binding to a number o f receptors (e.g. 
TLR4 and CD 14) and then signalling through a group o f Toll/interleukin-1 receptor 
(TIR)-adaptors for cytokine production. The QD-LPS micelles are taken up by these 
cells and remarkably they induce greater production o f cytokines than LPS alone. 
Importantly, these QD-LPS were found to be non-toxic, presumably because they 
were coated with a protecting layer o f ZnS, stearic acid and LPS and extremely small 
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4.1.1 Pathophysiology of Malaria
Malaria is an infectious disease caused by the protozoan parasite Plasmodium. It has 
been estimated that Malaria kills at least two million people annually, and that at least 
one third o f the world’s population is at risk o f acquiring it.1 The four species causing 
all human infections are P. falciparum, P. vivax , P. malariae and P. ovale. Infection 
by P.falciparum is the most severe o f the four and accounts for 90% o f deaths due to 
malaria. The life cycle o f P.falciparum consists o f a sexual cycle which takes place in 
the anopheles mosquito, and an asexual cycle which occurs in man and is responsible 
for producing the clinical effects and pathology associated with malaria. After the bite 
of an infected female anopheles mosquito sporozites are transferred intravenously into 
the human body (Figure 4.1). Then these sporozoites enter the liver where they 
undergo multiplication from just a few to thousands. This stage is called pre- 
erythrocytic stage. After this stage rupturing o f liver cells causes release o f merozoites 
which invade red blood cells (erythrocytes). Binding o f merozoites to erythrocytes 
begins the formation of intracellular parasites called trophozoites. In the erythrocytic 
stage, further development and multiplication o f plasmodium  within the erythrocyte 
takes place. Mitotic replication o f the parasite nucleus inside the red blood cell takes
place and then the parasite is called schizont. These schizonts are multiply rapidly for




Figure 4.1 Illustration of the life cycle of P. falciparum  in the human host and the 
anopheles mosquito vector (taken from Cowman et al. ).
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4.1.2 Overview of merozoite Invasion to Erythrocytes
Malaria merozoites have the very important role o f recognizing, attaching and 
entering erythrocytes (Figure 4.2 a). Initial attachment o f merozoites to erythrocyte is 
relatively weak (low affinity) and reversible. After initial interactions the erythrocyte 
surface is deformed and wrapped around the merozoite; this ensures the closer 
interaction o f the apical end of the merozoite with the erythrocyte membrane (Figure
4.2 b). Later a tight junction is formed between the merozoite and erythrocyte 
membrane aiding parasite entry. The actin myosin motor (proteins responsible for 
locomotion) o f the merozoite helps this tight junction to move inside the cells. Once 
this assembly enters fully inside the cells sealing o f the erythrocyte membrane takes 
place.3
Figure 4.2 (a) Malaria merozoites attacking erythrocytes and (b) events in merozoite
invasion (taken from Richard et at.4).
4.1.3 Molecular basis of invasion
A wide range o f proteins are involved in the recognition and invasion o f erythrocyte 
by the malaria parasite.
Several merozoite surface proteins (MSP-1, 2, 4, 5, 8  and 10) seem to be involved in 
the initial recognition. These proteins are linked to the merozoite surface by a 
glycosylphosphatidylinositol (GPI) anchor. Other merozoite surface proteins (MSP) 
like MSP-3, MSP - 6  and MSP-7 and MSP-9 are also associated partly with the 
merozoite surface. MSP-1 was the first merozoite surface protein to be discovered. It
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is a well characterized member o f MSP family and the most abundant protein on the 
merozoite surface . 5 MSP-1 is essential for parasite survival and invasion. Although 
MSP-1 is considered a suitable candidate for facilitating initial contact o f merozoite to 
the RBC definitive proof is still lacking. MSP-1 is formed during trophozoite and 
schizont stag and ranges in size between 180-225 kDa .6 There are two proteolytic 
maturation steps for MSP-1. The first cycle takes place at the schizont stage producing 
four polypeptides products which remain attached to parasite surface by the GPI 
anchor. The fragments masses are 83 kDa (N-terminus), 30 and 38 kDa (central 
regions), and 42 kDa (C-terminus). The second step happens at the time of 
erythrocyte invasion forming MSP1 19 fragment (11 kDa). M SPI19 is a leading 
candidate for malaria vaccine. ’ ’
After the initial contact/binding which is presumbably mediated by MSP-1, proteins 
harboured in secretory organelles in the apical end of the malaria parasite (rhoptries 
and micronemes; Figure 4.3) bind to specific receptors on the RBC; these proteins 
essential for invasion .3,7,8 One of this proteins is the Apical Membrane Antigen 1 
(AMA1); a leading antigen for the development o f a malaria vaccine since antibodies 
directed against it can prevent invasion .9 AMA-1 is a 83 kDa type 1 integral 
membrane protein which is stored in the microneme organelles o f the malaria parasite 
(Figure 4.3). At the time o f invasion AMA1 is transfered to the surface o f the parasite 
through the rhoptry neck. The precise role o f AMA1 and other proteins (e.g. actin 
myosin motors which seem to support the physical entry o f parasite into the 
parasitophorous vacuole) in erythrocyte invasion is still unclear. Thus, the 
development o f new ways to elucidate this important aspect is essential.
Figure 4.3 The structure of the P. falciparum merozoite (taken from Richard et ai.4h
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4.2 Controlling the number of functional groups 
attached to each QDs
For biological applications the ability to control the number o f ligands or functional 
molecules bound to each QD is very important as these molecules act as binding sites 
to the cell or cell receptors. Controlling the number of binding sites per QDs can also 
reduce the chances o f crosslinking and aggregation between QDs. However, in spite 
of recent synthetic advances, it is generally difficult to control the number of 
biomolecules which are attached to a single QD.10-13 In a recent study Sperling et a l u  
separated QDs with discrete number o f functional groups using gel electrophoresis. 
They prepared negatively charged polymer coated CdSe/ZnS QDs terminated with 
carboxylate groups and coupled each o f them to individual NH2 -PEG molecules using 
the EDC coupling method. After conjugation the QDs were separated with zero, one 
and two NH 2-PEG molecules on the basis o f their sizes using gel electrophoresis 
(conjugation o f NH2 -PEG molecules to QDs increases their size after coupling). Also 
recently, Carstaris et a /.15 managed to monofunctionalise QDs with DNA.15 
However, these methodologies are cumbersome and focused on minimising the 
number o f biomolecules that are attached to the QD-this is required for some 
biological applications.
4.3 Motivation for the work
In Chapter 2 we developed an strategy [based upon Ni(NTA)] surface modification of 
QDs and his-tag protein labelling) for site specific attachment o f proteins to QDs 
preserving biological activity. In Chapter 3 we used the large size and multivalent 
nature of QDs for developing strongly fluorescent materials which can be used to 
model the surface o f Gram negative bacteria and study how they interact and activate 
immune cells. In this Chapter we are going to use QDs as new materials for studying 
malaria parasite invasion of RBCs.
The aim was to exploit Ni(NTA)-QDs to anchor MSP 1 expressed with an histidine 
tag. Because binding o f MSP-1 to RBCs is weak multivalency may prove to be a 
critical aspect to achieve RBC binding (it has not been demonstrated using ‘free’ 
protein). Thus, another key objective of this work was to control the number o f MSP- 
1 protein molecules attached to each QDs. For this, we employ different types o f
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water soluble QDs in which the distance between the Ni-NTA units and the 
nanocrystal surface is varied by different linker groups. The general strategy is 
illustrated in Scheme 4.3. The results presented in this Chapter pave the way for the 
first study in which fluorescent nanoparticles are used for studying and enhancing the 
weak interactions between merozoites and RBC (Future work section).






Scheme 4.3 Approach adopted to control the number of protein molecules that can be 
attached to a single QD (in green and orange represents an arbitrary protein).
4.4 Experimental
4.4.1 Materials
All chemicals were obtained from commercial sources and used as received. Nickel
(II) chloride, jV-hydroxysuccinimide (NHS, 98%) and A-A-bis(carboxymethyl)-L- 
lysine hydrate were purchased from Sigma Aldrich. 1-Ethyl-3-[3’- 
(dimethylamino)propyl]carbodiimide was purchased from Ademtech. The 
hydrophobic (CdSe/ZnS core/shell QDs) and water soluble QDs (CdSe/ZnS core/shell 
QDs coated with DHLA) were prepared as described in Chapter 2, and the results 
presented here were obtained with QDs which had the first absorption band at 615 
nm, and a maximum emission peak at 620 nm with excitation at 380 nm. BCA protein 
Assay kit was purchased from Pierce Biotechnology. PBS IX buffer (pH 7.4) was 
purchased from Invitrogen. l,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
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(methoxy(polyethylene glycol)-2000) (mPEG2000 PE), l,2-dioleoyl-sn-glycero-3- 
[(N-(5-amino-l-carboxypentyl)iminodiacetic acid)succinyl] (nickel salt) and 1- 
palmitoyl-2-oleoyl-j,«-glycero-3-phosphocholine (PC) were purchased from Avanti 
Polar Lipids. Water soluble commercial QDs (CdSe/ZnS core/shell QDs with 
carboxylic acid group) were purchased form Ocean NanoTech, LLC. In this chapter 
these commercial QDs will be referred to as CQDs. Deep Purple Total Protein Stain 
was purchased from GE healthcare. Recombinant His6-MSP-l (His6 at the N 
terminus) was obtained from Lynne Harris and Dr David Cavanagh from The Institute 
of Immunology and Infection Research at the University o f Edinburgh.16 The MSP-1 
hybrid sequence used in this Chapter was:
MVTHESYQELVKKLEALEDAVLTGYSLFHKEKMILNEEEITTKGASAQSGAS 5 0  
AQSGASAQSGASAQSGTSAQSGTSGPSGPSGPSGTSGTSGTSGPSGTSGPSGTS 80  
GPSGTSGTSGTSGTSAQSGTSGTSAQSGTSGTSAQSGTSGTSPSSRSNTLPRSN 1 2 0  
TSSGASPPADASKDGANTQVVAKPADAVSTQSAKNPPGATVPSGTASTKGAI 1 6 0  
SSPGAANPSDDSSNEGTSGTAVTTSTPGSKGSVASGGSGGSVASSGSVTSGGS 2 0 0  
GGSVTSGGSVTSGGSGGSVASGGSVASGGSVASGGSVASGGSGGSVASVASV 2 4 7  
ASVASGGSGGSVASGGSGNSRRTNPSDNSS 2 5 0
This MSP-1 hybrid was chosen because recent studies have shown that antibodies to 
this sequence are associated with protection against clinical malaria.17' 19
4.4.2 Modification of quantum dots surface by NTA and NTA- 
Ni complex
The nitrilotriacetic acid-Ni (II) complex (NTA-Ni) was prepared by mixing N-N- 
bis(carboxymethyl)-L-lysine hydrate (NTA) (15 mg, 0.0396 mmole) and Ni(II) 
chloride (15 mg, 0.063 mmole) in HEPES (3 mL; 20 mM, pH 7.5) with stirring for 1 
hr. This complex was attached to DHLA-coated CdSe/ZnS QDs as described in 
Chapter 2. For CQDs, activation o f carboxylate groups was performed by mixing 20 
pL of QDs (8 pM). 100 pL of EDC (9 mM in HEPES) and 100 pL of NHS (9 mM in 
HEPES) with stirring for 30 min (this gives a QD concentration o f 0.72 pM). Then, 
100 pL o f the NTA-Ni2+ complex solution was added and the mixture was stirred for 
24 h. Excess nickel was removed by passing the solution through a 100 KDa nanosep 
filter. The NTA coated QDs were prepared in the same way using the NTA ligand 
instead o f NTA-Ni2+ complex. NTA and NTA-Ni2+ modified QDs were re-dissolved 
IX PBS buffer (50 pL, pH 7.4) for the protein binding studies with His6-M SP-l.
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4.4.3 Synthesis of QD-DOGS-Ni-NTA /PEG-PE and QD-DOGS- 
NTA /PEG-PE micelles
In a 5 mL round-bottomed flask, 100 pL of hydrophobic CdSe/ZnS QD (9.4 pM in 
chloroform), 50 pL o f l,2-dipalmitoyl-5H-glycero-3-phosphoethanolamine-N- 
methoxy(polyethylene glycol)-2000] (ammonium salt) (2 mg in 50 pL of chloroform; 
15 mM) and 20 pL o f l,2-dioleoyl-.sn-glycero-3-[(N-(5-amino-l- 
carboxypentyl)iminodiacetic acid)succinyl] (nickel salt) (0.2 mg in 20 pL of 
chloroform; 9.5 mM) were mixed together. The flask was left open at room 
temperature for 3 h in a fume hood to slowly evaporate the chloroform solvent. Any 
remaining chloroform was removed under vacuum using a rotary evaporator to form a 
thin film. The flask containing the QDs was then heated in water bath set to 80°C for 
30 s, after which 600 pL o f double distilled water was quickly added. Addition of 
water forms a suspension containing both empty micelles and those containing QDs. 
QD aggregates were removed from QD-DOGS-Ni-NTA/PEG-PE micelles by 
ultracentrifugation at 11,000 g for 2 min. Supernatant was collected which contains 
both empty micelles and those containing QDs. The empty micelles were removed 
with ultracentrifugation at 270,000g for 2x30 min. The micelles containing QDs 
formed a pellet while the empty micelles stayed suspended. The successive 
supernatants were discarded and the final QD-DOGS-Ni-NTA/PEG-PE micelles were 
resuspended in 600 pL o f water (this gives a QD concentration o f 30 nM). QD- 
DOGS-NTA/PEG-PE micelles were prepared by treating QD-DOGS-Ni-NTA 
micelles with EDTA (15 mM) and then passed through a Nanosep 100 kDa Omega 
membrane filter. Finally QD-DOGS-NTA micelles were resuspended in 400 pL of 
water (this gives a QD concentration of 25 nM).
4.4.4 Estimation of protein loading by BCA Assay (Enhanced 
Protocol)
The protein (His6-MSP-l) loading capacity o f the various QDs prepared was 
determined by BCA assays (Enhanced Protocol) as follows. Several QD: His6-MSP-l 
ratios were investigated. The following conditions were found appropriate to 
determine the maximum number o f His6-MSP-l each type o f QD can accommodate.
108
Chapter 4
CQD-NTA and CQD-Ni(NTA) {10 pL; 1.6 pM} was incubated with His6-MSP (10 
pL; 14 pM) for 2.0 h at 4°C.
QD-DOGS-NTA/PEG-PE micelle and QD-DOGS-Ni-NTA/PEG-PE micelle (10 pL; 
1.8 pM) was incubated with His6-MSP (9 pL; 14 pM) for 2.0 hr at 4°C. 
QD-DHLA-Ni-NTA (10 pL; 1 pM) was incubated with His6-MSP (8 |aL; 14 |uM) for
2.0 h at 4°C.
In each case the QD-protein complexes were separated from the unbound protein 
molecules by passing the solution mixture through a Nanosep 300 kDa filter (low 
protein-binding, modified polyethersulfone on polyethylene substrate). The retentate 
containing the QD-bound protein was treated with 100 pL of a PBS solution of 
imidazole (0.5 M, pH = 7.4) to release the protein. The filtrate was also made up to 
100 |aL using PBS. Then 2 mL of working reagent [a mixture o f solution A and B 
(50:1) as indicated in the manufacturer’s instructions] was added to the fractions 
(retentate and filtrate) and incubated at 60°C for 30 min. After incubation the 
absorbance o f the samples was measured at 562 nm using a CARY 300 SCAN UV- 
vis spectrometer.
4.4.5 Protein binding studies by sodium dodecyi sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE)
Protein binding studies were carried out by incubating 100 pL of the corresponding 
QD (1.3 pM) with 75 pL of His6-MSP-l (4.8 mg/mL; 68 pM) and His6-MSP-l 
protein for 2.0 hr at 4°C. The protein-QDs complexes were separated from the 
unbound protein molecules by passing this solution through a Nanosep 300 kDa filter 
(low protein-binding, modified polyethersulfone on polyethylene substrate). The 
retentate containing the QD-bound protein was treated with 175 pL of a PBS solution 
of imidazole (0.5 M, pH = 7.4) to release the protein. Similarly control retentate and 
filtrate fractions samples were prepared by using PBS. Retentate and filtrate fractions 
were analysed by SDS-PAGE as stated in Chapter 2.20 After the electrophoresis was 
finished, the gel was stained overnight using Deep Purple Total Protein Stain.
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4.5 Results and discussion
4.5.1 Synthesis of NTA and NTA-Ni surface-modified QDs
The hydrophobic (CdSe/ZnS core/shell QDs) and water soluble QDs (CdSe/ZnS 
core/shell QDs coated with DHLA) were prepared as described in Chapter 2 (section
2.3.2 and 2.3.4). The surface modification o f DHLA-coated QDs with NTA-Ni was 
accomplished as described in Chapter 2 (section 2.4.3). The absorption and emission 
spectrum of QD-DHLA-Ni (NTA) used in this study is shown in Figure 4.5 and 
Figure 4.6 respectively.
Figure 4.5 U.V-vis spectrum of QD-DHLA-Ni(NTA)(25 nM).
Wavelenath (nm)
Figure 4.6 Fluorescence emission spectrum of QD-DHLA-Ni(NTA) (25 nM) [Excitation at 
380 nm; Temperature = 25°C].
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Commercial QDs with carboxylate groups on the surface (CQDs) modified with NTA 
and NTA-Ni (CQD-NTA and CQD-Ni(NTA) were prepared also by activation with 
EDC/NHS and reaction with A-A-bis(carboxymethyl)-L-lysine. The absorption and 
emission spectra o f CQD, CQD-NTA and CQD-Ni(NTA) are shown in Figure 4.7 and 
Figure 4.8 respectively. The position o f the first excitonic peak and o f the emission 
band did not change upon attachment o f NTA and Ni-NTA units to these QDs. The 
fluorescence emission intensity, however, was reduced by ca. 30 % and 47 % after 
attachment o f NTA and NTA-Ni respectively.
Figure 4.7 U.V-vis spectra of CQD-NTA and CQD-Ni(NTA) (160 nM).
Wavelength (nm)
Figure 4.8 Fluorescence emission spectra of CQD, CQD-NTA and CQD-Ni(NTA) (160 
nM) [Excitation at 380 nm; Temperature = 25°C].
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QD-filled micelles decorated with NTA and Ni-NTA were prepared by adding 
DOGS-NTA-Ni and PEG-PE to hydrophobic QDs (QD-DOGS-NTA/PEG-PE and 
QD-DOGS-NTA-Ni/PEG-PE micelles). Several ratios o f the three reagents were 
used. It was found that an excess o f PEG-PE over DOGS-NTA-Ni is required (60:40 
was found to be enough) for good water solubility. Moreover, better results were 
obtained when the excess o f phospholipids relative to QD was high (500-1000:1). The 
absorption and emission spectra o f these micelles are shown in Figure 4.9 and Figure 
4.10 respectively. Also in this case the presence o f Ni2+ ions does not affect the 
position o f the emission band and the intensity is only reduced by ca. 10 %.
Wavelength (nm)
Figure 4.9 U.V-vis spectra of QD-DOGS-NTA /PEG-PE and QD-DOGS-Ni-NTA /PEG-PE 
(30 nM) micelle.
Wavelength (nm)
Figure 4.10 Fluorescence emission spectra of QD-DOGS-NTA /PEG-PE and QD-DOGS- 
Ni-NTA /PEG-PE micelles (30 nM) (Excitation at 380 nm; Temperature = 25°C).
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4.5.2 Protein binding studies
The non-covalent attachment o f His6-MSP-l to the QDs after derivatisation with Ni- 
NTA was analyzed by SDS-PAGE. A solution o f the QD and control (PBS) was 
incubated with the His6-MSP for 2 h and passed through a Nanosep 300 kDa 
centrifugal device. The retentate was redissolved in PBS buffer, and both retentate 
and filtrate were analyzed by SDS-PAGE. As expected from the results obtained in 
Chapter 2, HÍS6-MSP-1 was captured by the Ni-NTA modified QDs. Figure 4.11 
shows the gel obtained when QD-DHLA-Ni (NTA) was incubated with 38 molar 
equivalent o f His6-MSP-l.





Figure 4.11 SDS-PAGE of the retentate (R) and filtrate (F) after ultrafiltration through a 
Nanosep 300 KDa filter of His6-MSP (a) and His6-MSP incubated with QD-DHLA-Ni(NTA) 
(b) Lane M contains size markers. Deep Purple Total Protein Stain was used in this 
study.
The loading capacity o f CQD-NTA, CQD-Ni (NTA) QD-DOGS-NTA /PEG-PE 
micelle, QD-DOGS-Ni-NTA /PEG-PE micelle and QD-DHLA-Ni (NTA) for His6- 
MSP-1 was estimated by enhanced BCA assays.
When CQD-Ni (NTA) (1.6 x 10'" moles) were incubated with His6-MSP (1.4 x 10'10 
moles) it was found that ail the His6-MSP molecules had been attached to the QDs. 
Even after decreasing the amount o f CQD-Ni(NTA) two fold (0.8 x 10 11 moles) it 
was found that all the His^-MSP molecules had been attached to the QDs. When the 
amount o f CQD-Ni(NTA) was decreased to 0.4 x 10'" moles, only 2.23 x 10'" moles
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of protein was attached. Moreover, no protein binding was observed when the amount 
o f CQD-Ni(NTA) was reduced to 0.2x1 O'11 moles. From these results it can be 
deduced that under these conditions ~18 molecules o f His6-MSP-l can be loaded on 
each QD.
On incubation o f QD-DOGS-Ni-NTA/PEG-PE micelle (1.82 x 10'11 moles) with His6- 
MSP-1 (1.28xlO‘10 moles) it was found that all the His6-MSP-l molecules had been 
attached to the QD-DOGS-Ni-NTA /PEG-PE micelle. When the amount o f QD- 
DOGS-Ni-NTA /PEG-PE micelle was decreased to 1.16 x 10~n moles, only 7x10"'1 
moles o f protein were attached. It seems that under these conditions ~7 molecules of 
His6-MSP-l can be loaded on each QD micelle. It is important to note that under the 
same experimental conditions QD-DOGS-NTA/PEG-PE micelle did not show any 
binding to His6-MSP-l.
As expected, the smallest QDs had the lowest protein binding capacity. Thus, when 
QD-DHLA-Ni (NTA) (1.1 x 10'11 moles) were incubated with His6-MSP-l (1 x 10'10 
moles) it was found that only 5 x 10'11 moles of His6-MSP molecules were attached to 
the QD (i.e. ~5 molecules of His6-MSP can be loaded on each o f these QDs).
Thus, the highest protein loading capacity was found in CQD-Ni(NTA), whereas the 
lowest was found for QD-DHLA-Ni (NTA). In essence, by changing the size o f the 
linker separating the nanocrystal surface from Ni-NTA (protein recognition unit) it is 
possible to control the number of MSP 1 molecules. It will be exciting to investigate 
the RBC binding ability of these constructs (see Future work).
4.6 Summary and Conclusion
We have demonstrated that NTA-Niohistidine tag recognition and the multivalent 
properties of QDs can be used for attaching multiple copies o f His6-MSP-l proteins to 
a single QD. Several NTA-Ni modified QDs were successfully prepared. All 
exhibited His6-MSP-l binding capacity. The His6-MSP-l loading capacity ranged 
from 18 to 5, and is consistent with the length o f the linker separating the nanocrystal 
and Ni-NTA complexes. This result paves the way for studies in which the binding 
ability of inorganic nanoparticles carrying a different number o f MSP-1 molecules 
can be systematically investigated. Moreover, it provides further evidence that QDs
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5.1 Conclusions, Implications and Future Work
In this thesis various strategies for preserving and enhancing the activity o f 
biomolecules on QDs were successfully devised (Figure 5.1).
In Chapter 2 hydrophobic CdSe-ZnS core-shell QDs made water-soluble by ligand 
substitution with the bifunctional ligand dihydrolipoic acid (DHLA) were further modified 
with nickel complexes o f nitrilotriacetic acid (Ni-NTA). These QDs were able o f in one step 
selectively purifying and labelling an His6-tagged GST. An important aspect of this study was 
to investigate the extent to which the mode o f attachment (site specific versus non specific) 
affects the catalytic activity o f the GST on the QD surface. It was found that the Ni-NTA 
sites specifically recognize the His6 tags. This recognition enabled docking the QD away 
from the active site o f the GST homodimer resulting in retention o f catalytic activity. In 
contrast, non-specific attachment o f the Ni-NTA modified QDs to GST lacking the His6 tag 
led to loss o f activity. Because His-tags have been broadly adopted in the molecular biology 
and biochemistry communities, this specific conjugation strategy should enable widespread 
use o f these QDs for a broad range o f biological applications.
In Chapter 3 the possibility o f exploiting the multivalency and large size o f QDs to 
mimic pathogens like bacteria and viruses was investigated for the first time. An important 
discovery was that it seems that cooperativity between different biomolecules on the same 
QD can in some cases lead to enhanced biological activity. In this case hydrophobic 
interactions and micelle formation (instead of ligand substitution) were used to functionalize 
the hydrophobic CdSe-ZnS QDs with the lipopolysaccahride (LPS) Kdo2-Lipid A LPSs are 
found in outer membrane o f Gram-negative bacteria. Because LPS are potent stimulants of 
the mammalian immune response they can be both highly toxic and useful as adjuvants 
(immune potentiators) for the development o f more effective vaccines.’QD-LPS micelles 
prepared in this thesis work induced stronger production o f cytokines in macrophages and 
dendritic cells than control LPS in vitro. Importantly, when they were co-injected with a 
model antigen (DNP-OVA) in mice they generated higher production o f antibodies in vivo 
than LPS alone and even than LPS emulsified in incomplete Freund’s adjuvant -which is the 
gold standard in adjuvant potency. These results have important implications. It may be 
possible to exploit QDs both as tools to investigate how a wide range o f pathogen associated
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molecular patterns are processed in vitro and in vivo and to modulate the immune responses 
they induce in a controllable way.
In Chapter 4 the discoveries made in the previous chapters were integrated towards 
creating the first example o f a QD-based model for the Plasmodium falciparum  malaria 
merozoite. In this parasite the surface is predominately coated with the protein MSP-1. An 
His6-MSP-l protein was successfully attached to three different Ni-NTA functionalized QDs. 
Importantly, it was possible to control the number of MSP-1 molecules loaded onto each QD 
by using different linkers. The implication o f this work is that it will be possible to apply 
these or similar constructs to investigate the extent to which MSP-1 and it’s density on the 
merozoite surface influences it’s binding to red blood cells-a process which is critical in the 
malaria parasite life cycle.
In conclusion the results presented in this thesis work suggested that QDs can be used 
efficiently for preserving and enhancing the activity of biomolecules. These results open up 
new biological applications for QDs.
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Figure 5.1 Approaches used in this thesis for preserving and enhancing the activity of 
biomolecuies on QDs.
It should be possible to extend this work in many different ways.
First o f all, antigen-containing micelles containing QDs should be prepared for 
studying if  and how having an antigen and immune potentiator (e.g. LPS, CpG DNA etc.) 
attached to the same nanoparticle affects the immune responses generated. Recent studies 
have suggested that this is an extremely important aspect with exciting potential.2 To 
accomplish this DOPGS-Ni-NTA/PEG-PE and LPS polymers could be co-incorporated in the 
QD-filled micelles for site specific immobilization o f his-tag protein antigens. An important 
target antigen should ovalbumin (OVA). OVA is a well-characterised protein with a good 
availability o f useful resources including T-cell receptor transgenic mice (e.g. OT-II), peptide 
antigens containing defined epitopes and monoclonal antibodies. It is also a highly 
manipulable antigen (e.g. it can be readily prepared in recombinant, immunogenic form with 
a His6-tag3 for site-specific binding to our Ni-NTA containing QDs). The native protein is a 
45 kDa protein with a diameter o f around 5 nm, so theoretical calculations based on the size
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of QDs and this protein, the QD:OVA ratios can be varied from 1 to the theoretical maximum 
o f -12-17 (for 3-10 nm QDs). Peptide antigens encoding transgenic T-cell receptor (TCR) 
epitopes from the OVA protein will also be used (e.g. the OT-II epitope n- 
ISQAVHAAHAEINEAGR-COOH ; -  45-250 could be theoretically attached to 3-10 nm 
QDs). His6-OVA could also be attached to the QD-DHLA-NTA-Ni, CQD-NTA-Ni, and QD- 
DOGS-Ni-NTA micelles already available from the work described in this thesis. It could be 
interesting to investigate the effect that the various linkers and different protein loading 
capacity provided by these systems have on antigenicity of ovalbumin attached to QDs
Later it would important to extend the results with OVA to an antigen with exciting 
medical potential like MSP-1, which is a protein expressed by Plasmodium falciparum  and 
Plasmodium chabaudi, the protozoan parasites which cause malaria in humans, and it’s 
corresponding model diseases in mice, respectively. 4  Also exciting would be the attachment 
of other pathogen associated molecular patterns (e.g. CpG DNA).5 In doing so, it should be 
possible to better mimic the multivalency and ‘cocktail’ o f biomolecules encountered by the 
immune system when interacting with microbial pathogens in vivo.
In Chapter 4 we have optimised the methods and conditions to control the 
stoichiometry o f biomolecules for each QD. It would be interesting to examine the binding of 
this QD-His6-MSP-l hybrid to RBCs using techniques like fluorescence activated cell sorting 
(FACS) and confocal microscopy. As these techniques will allow to monitor in real time the 
binding events which may be responsible for the initial recognition and contact between the 
malaria merozoite and RBCs. These studies could be followed by in vitro and in vivo studies 
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